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ABSTRACT 
 
Regulator of G protein signaling protein 2 (RGS2) attenuates G Protein-Coupled Receptor 
(GPCR) signaling by promoting the hydrolysis of GTP in the activated Gα subunit to GDP, 
thereby governing many physiological and pathophysiological signals. However, how RGS2 
itself is regulated remains to be elucidated. In this study, our principal goal was to discover the 
molecular mechanisms controlling RGS2 degradation and if altered degradation affects Gα 
signaling. RGS2 has four initiation sites (at residues 1, 5, 16, and 33), resulting in the existence 
of four distinct N-terminal initiation site variants. Additionally, there are naturally occurring 
mutations in this region at residues 5 (RGS2 M5V), 14 (RGS2 R14I), 18 (RGS2 K18N) and 
23 (RGS2 G23D), which may be associated with a phenotypic profile seen in individuals with 
the mutant forms. Here we report that the use of each initiator methionine residue, as well as 
mutations within the N-terminus of RGS2, can have profound effects on RGS2 half-life. 
Additionally, we show a correlation between RGS2 half-life and the ability to attenuate Gαq/11 
signaling. Finally, we provide evidence that RGS2 is degraded via the ubiquitin-proteasome 
pathway. Considering the importance of RGS2 in pathophysiological conditions, altered 
degradation associated with initiation variants or mutant isoforms could be contributing to such 
conditions.  
Key Words 
G protein-coupled receptors (GPCR), Regulator of G protein signaling proteins 2 (RGS2), 
GTPase accelerating proteins (GAPs), protein degradation, single nucleotide polymorphisms 
(SNPs), cell signaling. 
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1 INTRODUCTION 
1.1  G PROTEIN SIGNALING 
1.1.1 G PROTEIN SIGNALING OVERVIEW 
G Protein-Coupled Receptors (GPCRs) are seven transmembrane domain-spanning proteins 
that constitute one of the largest receptor classes within the human body1. The human genome 
is reported to contain greater than 720 GPCRs2. GPCRs have numerous physiological and 
pathological roles due to the transduction of extracellular signals into intracellular effector 
pathways through receptor activation1. Receptor activation may occur from a broad range of 
ligands including proteins, peptides, and organic compounds1. Upon activation, GPCRs turn 
on heterotrimeric G proteins by promoting the binding of the activating nucleotide GTP in 
exchange for GDP on the G protein’s Gα subunit1. The Gα subunit, along with the bound GTP, 
is thought to dissociate from the Gβγ dimer, with both complexes subsequently able to 
modulate the activities of a variety of effectors3. Gα signaling is dependent on which Gα family 
(i.e., Gαs, Gαq/11, Gαi/o, Gα12/13) is activated (Table 1.1). Gαs activates, while Gαi/o inhibits, 
receptor-dependent adenylyl cyclase function, leading respectively to an increase or decrease 
in the second messenger cyclic adenosine monophosphate (cAMP)3. The Gαq/11 G protein 
family couple receptors to phospholipase Cβ (PLC-β) to increase the levels of the second 
messengers inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG), subsequently 
leading to an increase in cytosolic calcium (Ca2+) and the activation of protein kinase C (PKC)3. 
The Gα12/13 G protein family members activate RhoGTPase nucleotide exchange factors 
(RhoGEFs) which in turn activate a small monomeric GTPase, RhoA, and other downstream 
effectors2. These GPCR-mediated signaling pathways are involved in many human diseases, 
and are thus the focus of approximately 30-40% of today’s commercially available drugs4. 
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Table 1.1. Classes of Gα subunits, their expression pattern, and their effectors 
Members of the Gα family, their expression patterns, and their signaling functions 
Gαs Gαs Ubiquitous 
Stimulation of adenylyl cyclase 
Gαolf Olfactory neurons 
Gαi/o Gαi1/2/3 Ubiquitous 
Inhibition of adenylyl cyclase 
Closes Ca2+ channels 
GαoA/B Brain 
Gαot1/2 Retina Stimulation of cGMP-phosphodiesterase 
Gαz Brain/platelets Inhibition of adenylyl cyclase 
K+ channel closure 
Gαq/11 Gαq/11 Ubiquitous 
Stimulation of PLC-β 
Activate RhoGEFs 
Gα15/16 Hematopoietic cells 
Gα14 Lung, kidney, liver 
Gα12/13 Gα12/13 Ubiquitous Activate RhoGEFs 
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G protein activation is terminated by the intrinsic GTPase activity of the Gα subunit, which 
hydrolyzes the GTP back to GDP, resulting in the reformation of the inactive Gαβγ 
heterotrimer (Figure 1.1). After activation, GPCRs may undergo receptor internalization, and 
many are able to signal from endosomal compartments, primarily via G protein-independent 
mechanisms5. This process appears to be regulated by phosphorylation by GPCR Kinases 
(GRKs) and arrestin binding5,6. There are diverse mechanisms within a cell that regulate the 
magnitude and duration of G protein signaling. Nucleotide exchange can be modulated by 
Guanine nucleotide Exchange Factors (GEFs) and Guanine nucleotide Dissociation Inhibitors 
(GDIs), whereas the GTPase activity of the Gα subunit may be enhanced by GTPase 
Accelerating Proteins (GAPs)7 (Figure 1.2). One family of GAPs are the Regulator of G 
protein Signaling (RGS) proteins, which promote the hydrolysis of GTP on the activated Gα 
subunit to GDP, thereby curtailing GPCR signaling8. The RGS protein family, including RGS-
like proteins, contain more than 30 members, of which most act as GAPs by binding to and 
deactivating Gα proteins9. The majority of RGS proteins act upon Gαi/o, with a subset acting 
upon Gαq/1110. One protein, RGS2, however, is unique in that it preferentially acts upon Gαq/11 
over Gαi/o, while maintaining the ability to impede adenylyl cyclase activity to obstruct 
signaling via Gαs. The mechanism resulting in the inhibition of Gαs signaling by RGS2 remains 
controversial. It has been suggested to be caused by the binding of Gαs and RGS2, but also the 
binding of certain isoforms of adenylyl cyclase with RGS211. The fundamental role of RGS2 
has been extensively researched as it is important to understand how such an abundant receptor 
class such as GPCRs are regulated. However, it is unknown how RGS2 itself is regulated. In 
the following study, we used an RGS2 overexpression model as a tool to study how RGS2 is 
regulated, specifically the rate of degradation of RGS2, and how this could contribute to Gα 
signaling. 
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Fig 1.1. Receptor-mediated activation of G proteins. The binding of an extracellular ligand 
to the GPCR causes a conformational change in the receptor, which leads to the activation of 
the Gα subunit. This activation promotes the exchange of GDP for the activating nucleotide 
GTP and is thought to cause the dissociation of the Gβγ dimer from the complex. Both the 
GTP-bound Gα and free Gβγ are capable of initiating downstream signals by interacting with 
effectors. This process is terminated by the intrinsic GTPase activity of the Gα subunit which 
can hydrolyze the GTP back to GDP, forming the inactive Gαβγ heterotrimer complex. 
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Fig 1.2 Regulation of G protein signaling. The rate of nucleotide exchange can be altered by 
guanine nucleotide dissociation inhibitors (GDIs) such as RGS12 and guanine nucleotide 
exchange factors (GEFs) such as GPCRs. GTP hydrolysis can be regulated by GTPase 
accelerating proteins (GAPs) such as RGS proteins. 
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1.1.2 Gαq/11 SIGNALING 
Upon ligand binding, GPCRs have the ability to activate G proteins by promoting the exchange 
of a GDP nucleotide for the activating GTP nucleotide on the Gα subunit of the G protein3. 
Intracellular signaling is dependent upon which G protein family is activated. Gαq/11 signaling 
begins when the enzyme PLC-β is activated by the G protein3. PLC-β catalyzes the hydrolysis 
of the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into two secondary 
messengers: IP3 and DAG
12. IP3 diffuses throughout the cytosol and binds to IP3 receptors 
located on the endoplasmic reticulum (ER) or the sarcoplasmic reticulum (SR) in order to 
release calcium (Ca2+)13. Due to the higher Ca2+ concentration within the ER compared to the 
cytosol, activation of IP3 receptors causes a rapid rise in cytosolic Ca
2+ levels12.  
One role of Ca2+ and DAG is to promote the activation of some isoforms of the enzyme protein 
kinase C (PKC)12. PKC has a major role in regulating many cellular functions including 
transcription of certain genes, regulating many membrane receptors and ion channels, 
regulating many cellular phosphorylation cascades12, cytoskeleton remodelling, and cellular 
survival signals14. Ca2+ has other intracellular functions, including binding to and activating 
the intermediate messenger calmodulin (CaM)15,16. CaM mediates many cellular processes 
such as inflammation, metabolism, apoptosis, smooth muscle contraction, memory, and 
immune response15. CaM is able to activate a protein phosphatase, calcineurin (CaN), by 
binding to a regulatory domain within CaN, causing a conformational change and resulting in 
activation of the phosphatase17. CaN can trigger the activation of the transcription factor 
Nuclear Factor of Activated by T-cells (NFAT)18. NFAT can regulate gene transcription 
including the upregulation of hypertrophic response genes, which may lead to cardiac 
hypertrophy18. Gαq/11 can also signal in a PLC-β-independent manner. The Rho GTPase family 
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belongs to the Ras superfamily and have a role in many cellular processes such as secretion, 
smooth muscle contraction, migration, neurite retraction, and gene transcription19. Rho 
proteins cycle between inactive GDP-bound and an active GTP-bound state, and this activation 
is catalyzed by GEFs (i.e., RhoGEFs)19. It is well known that Gα12/13 G proteins activate 
RhoGEFs. It has only been recently shown that p63RhoGEF links specifically Gαq/11-coupled 
receptors to RhoA by a direct interaction with GTP-liganded Gαq/11 proteins19. This discovery 
provides another avenue for Gαq/11 to signal through, adding to the complexity of G protein 
signaling. Clearly, the Gαq/11 signaling pathway followed can depend on many factors such as 
which Gαq/11-coupled GPCR is activated.  
1.1.3 Gαs SIGNALING 
Gαs signaling begins the same way as Gαq/11 signaling – ligand binding causes a conformational 
change in the GPCR, allowing for the activation of the G protein. Gαs signaling is mediated by 
the activation of adenylyl cyclase from the Gαs-GTP complex20. Adenylyl cyclase catalyzes 
the cyclization of 5’-Adenosine Triphosphate (ATP) to the second messenger cyclic adenosine 
monophosphate (cAMP)21. cAMP is an important second messenger that can activate several 
different signaling proteins including the enzyme Protein Kinase A (PKA, or cAMP-dependent 
protein kinase)22. PKA is a tetramer composed of two catalytic domains and two regulatory 
domains. When present, the regulatory subunits bind cAMP and release the catalytic domains 
which can phosphorylate target proteins22. PKA has several cellular functions including 
regulation of glycogen, sugar, and lipid metabolism23, sequestering Rac to control cytoskeleton 
remodeling24, activating the reward system25, vasodilation26 and renin secretion27. PKA is well-
known for regulating transcription by phosphorylating various transcription factors including 
9 
 
 
 
cAMP-response element-binding protein (CREB), cAMP-responsive element modulator 
(CREM), and activating transcription factor 1 (ATF1)28.  
An important downstream effector in the cAMP-dependent pathway is Exchange Protein 
directly Activated by cAMP (EPAC). EPAC is a Guanine nucleotide Exchange Factor (GEF) 
that promotes the activation of small GTPases, such as Rap1, whose major function is to 
increase cell adhesion via integrin receptors28,29. Another cAMP-dependent function is to bind 
to and modulate a family of cyclic-nucleotide-gated ion channels that conduct calcium28. The 
Gαs pathway can be quite variable and has many pathways to choose from. It is thought that 
complex molecular mechanisms must be occurring to allow cross-talk between the pathways. 
This cross talk will allow the pathways to agonize or antagonize each other to ultimately get 
the desired response of the specific receptor-bound ligand29.  
1.1.4 STRUCTURAL BASIS OF Gα ACTIVATION 
All Gα proteins are composed of two domains: a GTPase domain and a helical domain30. The 
GTPase domain contains three flexible loops that undergo substantial structural changes during 
nucleotide exchange and the hydrolysis cycle31. The GTPase domain hydrolyses GTP and also 
contains binding sites for Gβγ, receptors, and effectors30. The helical domain of the Gα subunit 
is composed of a six α-helix bundle that forms a cap over the nucleotide-binding site in order 
to bury the bound nucleotide within the protein30,31. The helical domain is unique to each of 
the heterotrimeric G proteins suggesting it may regulate coupling of specific G proteins and 
other regulators32. 
Although GPCR-stimulated GDP release is not fully understood, several mechanisms have 
been proposed30. One model suggests that upon GPCR activation, the receptor uses the N-
10 
 
 
 
terminal helix of Gα as a lever arm to pull Gβγ away from Gα, resulting in GDP release30. A 
second model suggests that the receptor uses the N-terminal helix of Gα to force Gβγ into Gα, 
allowing Gγ to engage the helical domain of Gα, resulting in GDP release30. Independent of 
either model, the higher cellular GTP concentration relative to GDP means that GTP will more 
likely bind to the transient nucleotide-free state of Gα30, causing Gα protein activation. In 
addition, the binding of GTP to Gα can be facilitated and stabilized by magnesium (Mg2+), 
which has been suggested to act as a keystone locking the Gα in a conformation that favours 
dissociation from Gβγ and effector binding33. The intrinsic GTP hydrolysis varies among 
different Gα proteins34, however, the relatively slow GTPase activity of Gα subunits (other 
than Gαs) can be enhanced by GAPs. 
1.2 REGULATOR OF G PROTEIN SIGNALING (RGS) PROTEINS 
The duration of G protein signaling is determined by the length of time that the Gα subunit is 
in the GTP-bound or activated state35. GTP hydrolysis was originally thought to be an 
unregulated function of Gα subunit that provides intrinsic control over the activation period of 
a G protein35. However, there remained an inconsistency between the rapid G protein signal 
inactivation rates in vivo and relatively slow GTP hydrolysis rate in vitro36,37. This suggested 
there is a mechanism in vivo regulating the intrinsic GTPase activity of Gα that could accelerate 
the process. One family of proteins that are known to serve such a role are Regulators of G 
protein Signaling (RGS) proteins. 
SST2, Egl-10, G0S8 (later renamed RGS2), and GAIP (RGS19) were among the first RGS 
proteins identified in the mid 1990s38,39,40,41. Since the 1990s, more than 30 RGS proteins, 
including RGS-like proteins, have been discovered and added to the RGS family9,42. All RGS 
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proteins share an RGS domain of approximately 120 amino acids which mediates the GAP 
activity of the RGS protein. There are four subfamilies based on their sequence similarity in 
the RGS domain: A/RZ, B/R4, C/R7, and D/R12 (Figure 1.3). Although many RGS proteins 
are relatively simple proteins, containing little more than an RGS domain, some RGS proteins 
contain additional functional domains other than the RGS domain. Thus, RGS protein may 
have non-canonical functions distinct from deactivating Gα subunits43. 
1.2.1 RGS PROTEIN-G PROTEIN BINDING 
RGS proteins have the ability to bind to the active state of Gα proteins and increase the rate of 
GTP hydrolysis upwards of 2000 fold45. The molecular and structural mechanism of RGS 
proteins GAP activity has been extensively studied. The classical RGS domain consists of 9 α-
helices bundled into two lobes. One lobe is formed by helices αI, αII, αIII, αVIII, and αIX 
whereas the other lobe consists of the αIV, αV, αVI, and αVII helices46,47. The RGS domain 
has been shown to be crucial in the G protein-RGS protein interface by both NMR and 
crystallography, and this interaction is important to mediate a RGS protein’s GAP activity46,48. 
It is likely that the interaction between the αVII and αVIII helices of RGS domain and the Gα 
helical domain is what allows for selectivity between different RGS protein and G proteins47,49.  
1.2.2 MECHANISMS OF RGS PROTEIN GAP ACTIVITY 
The mechanism of RGS protein GAP activity was first studied using RGS4-Gαi1 as a 
model46,50. It was concluded that RGS4 stimulates GTP hydrolysis primarily by binding to and  
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Fig. 1.3. Structures and classification of mammalian RGS proteins. RGS proteins are 
classified into subfamilies based on the alignment of RGS domain amino acid sequences. 
Proteins are oriented with their N termini on the left and their C termini on the right. 
Abbreviations: RGS: Regulator of G protein signaling; DEP: Dishevelled, worm EGL-10, and 
mammalian Pleckstrin; R7H: R7 binding proteins; GGL: G game like; PDZ: PSD95, Dgl and 
ZO-1/2; PTB: protein tyrosine binding; RID:  Ras interaction domain. Colours: Blue: 
Amphipathic helix; Green: GoLoco motif; Yellow: Coiled coil domain. Adapted from 
Hollinger and Hepler, 2002, with permission44.  
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creating an environment that favours the transition state conformation of the Gα subunit which 
is most likely to hydrolyse GTP50. The crystal structure of RGS4 bound to the transition state 
of Gαi1 (i.e., with GDP and AlF4- in the binding pocket, mimicking the conformation of the 
GTP-activated form that precedes GTP hydrolysis) provided supplementary information about 
the interaction between RGS protein and G protein. It was shown that RGS4 does not directly 
interact with either GDP or AlF4
-51. Instead, RGS4 catalyzes GTP hydrolysis by reducing the 
energy of the transition state of the Gα subunit and destabilizing the Gα-GTP complex46. 
Additional studies using other RGS-Gα complexes such as RGS16/Gαt and RGS9/Gαt52,53, 
p115-RhoGEF/Gα13/i154, RGS1/ Gαi/o, and RGS19/Gαi/o55, each confirmed that the RGS 
domains bind to and stabilize the flexible regions of Gα during the transition state of GTP 
hydrolysis. 
1.2.3 SELECTIVE REGULATION BY RGS PROTEINS 
The selectivity of RGS proteins is dependent on the amino acid residue sequence elements 
within the RGS domain, as well as the helical domain of the Gα protein39. The vast majority 
of RGS proteins are selective for the Gαi/o and Gαq subfamilies of G proteins, but their affinity 
toward different G proteins varies somewhat within these two subfamilies. For example, RGS4 
is known to interact strongly with both Gαi/o and Gαq56 but RGS19 interacts strongly with Gαi1, 
Gαi3, and Gαo, while maintaining the ability to weakly bind Gαi2 but not appearing to bind with 
Gαs or Gαq at all57. The available crystal data suggests that RGS19 has a serine at the position 
corresponding to the asparagine position in RGS4, which may contribute to the difference in 
G protein selectivity46,58. Recently, studies have identified many other RGS proteins can also 
regulate Gαq/11 signaling functions, although not block Gαq/11 signaling by accelerating Gα-
GTPase activity59. For example, GRK2 contains an RGS domain that binds tightly to Gαq to 
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block its interactions with PLC-β without affecting Gαq/11-GTPase activity59. Thus, the effector 
antagonism of RGS proteins can be more complex than simply the binding to G proteins. 
The N-terminal regions of RGS proteins serve as important determinants for their biochemical 
selectivity. Each of the subfamilies of RGS proteins contain N-terminal regions with diverse 
structural features. The R4/B subfamily each have an amphipathic α-helix of about 30 amino-
acid residues with multiple palmitoylation sites60. The RZ/A subfamily have a cysteine-rich 
domain referred to as a cysteine string motif61. In other RGS subfamilies, molecular domains 
such as the DEP domain (R7/C subfamily) or PDZ domain (R12/D) are near the N-terminus 
of the protein. The N-terminus of RGS proteins regulates selectivity by either mediating RGS 
protein sub-cellular localization or making direct contact with specific GPCRs or effector 
proteins62. For example, deletion of the N-terminus of RGS2 greatly reduces its plasma 
membrane and nuclear localization63. 
Though all RGS proteins share a similar RGS domain, there are very different tissue expression 
patterns among different RGS proteins. For example, RGS2 is ubiquitously expressed 
throughout all cells, suggesting a more general function39. On the other hand, RGS9-1 is solely 
expressed in the retina, while its splice variant RGS9-2 is expressed in certain regions of the 
brain64,65. Other examples include RGS5 being highly expressed in the vascular tissue with 
lower expression in skeletal muscle and kidney tissue66 and RGS21 expression in taste bud 
cells67. The relatively specific tissue distribution of RGS proteins suggests that there may be 
specialized roles of each RGS protein. 
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1.2.4 NON-CANONICAL FUNCTIONS OF RGS PROTEINS 
RGS proteins contain other molecular domains outside of the conserved RGS domain that have 
binding partners other than Gα subunits of G proteins and thus function to regulate either their 
subcellular localization, GAP activity, or receptor coupling. These additional domains may 
enable RGS proteins to serve non-canonical functions and limit signaling via GAP-
independent mechanisms such as effector antagonism and GDI43. RGS proteins can also bind 
many different effector proteins such as adenylyl cyclases, PLC-β, and G protein-coupled 
inwardly-rectifying potassium (GIRK) channels42. In some cases, RGS proteins can bind to 
effectors and interfere with the productive interaction between these two proteins, thus, RGS 
proteins function as effector antagonists68. On the other hand, RGS proteins may also serve as 
anchors and create RGS-G protein-effector complexes, resulting in rapid transduction and 
temporal focusing of the G protein signal9. 
Regulation of non-G protein signaling by RGS proteins has also been investigated. Both 
RGS13 and RGS16 have been found to interact with the p85α subunit of phosphatidylinositol 
3-kinase (PI3 kinase) in a G protein-independent manner, and thus inhibit signaling events 
downstream of PI3 kinase69,70. RGS3 has been shown to interact with the Smad family of 
proteins to interfere to TGF-β-induced dimerization of Smad3 and Smad4, thereby inhibiting 
Smad-mediated gene transcription71. Other RGS or RGS-like proteins have been suggested to 
play a role in regulating nuclear signaling, for example, by modulating gene transcription43. 
Work done by our lab has identified a novel inhibitory role of RGS2 on global protein 
synthesis, wherein RGS2 interacts with the ε subunit of eIF2B to inhibit its GEF activity on 
eIF272. 
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1.2.5 PATHOPHYSIOLOGICAL FUNCTIONS OF RGS PROTEINS 
Characterizing the specific roles of RGS proteins in the context of whole-organism 
homeostasis and pathophysiology has been a major concerted effort in the field and knockout 
mouse strains have been essential to these discoveries73. Knockout animals have shed light on 
the importance of RGS proteins in many physiological conditions. RGS1-deficient mice 
showed abnormal responses to chemokines and improper maturation of germinal centers74, 
whereas RGS13-deficient mice showed a different immune system phenotype which resulted 
in increased mast-cell degranulation and anaphylaxis69. RGS2-deficient mice have a 
completely different immune issue in that their B cell quantities and differentiation are normal, 
however, they are unable to mount a robust T cell immune response73. RGS2 is ubiquitously 
expressed throughout all cells types which is presumably why RGS2-deficient mice exhibit 
many abnormal phenotypes. Besides immune issues, RGS2-deficient mice also show increased 
anxiety and decreased male agression75, decreased fat stores76, and constitutive hypertension 
due to a decreased inhibitory influence on Gαq/11-mediated vasoconstriction77–79.  
Other RGS-deficient mice also show dysregulation in the cardiovascular system. Mice 
deficient in RGS5, which is mainly found in vascular smooth muscle and pericytes, exhibit 
constitutive hypotension73. Mice deficient in RGS4, a RGS protein with high expression in the 
sinoatrial node of the heart, experience exaggerated decreases in heart rate when the 
parasympathetic nervous system is activated73. Finally, RGS6-deficient mice have a mild 
resting bradycardia and altered heart rate responses to pharmacological agents73. 
Alterations in RGS pathways have been implicated in several disease states, especially 
cancer80. Prostate cancer, head and neck squamous cell carcinoma, breast cancer, and lung 
17 
 
 
 
cancer all demonstrate variable risk with alterations in the RGS pathway80. There is increasing 
evidence that point mutations or Single Nucleotide Polymorphisms (SNPs) within RGS genes 
may predispose individuals to disease states associated with RGS protein pathways. For 
example, SNPs located on the RGS4 gene have been associated with bladder cancer80 and also 
with schizophrenia81. RGS SNPs have also been linked to several other human diseases 
including celiac disease82, anxiety and panic disorders83, platelet hypofunction84, and 
hypertension85,86. Extensive research has not been performed on these SNPs, as most have just 
been identified as potential contributors to physiological disease states. Both genome-wide 
association studies and molecular mechanistic studies need to be performed in order to confirm 
the role RGS SNPs play in disease development. 
1.2.6 RGS PROTEINS AS POTENTIAL DRUG TARGETS 
GPCRs and their linked signaling pathways are the direct targets for a vast majority of currently 
used pharmaceuticals87,88. RGS proteins have a unique ability to modulate G protein signaling 
combined with highly regionalized localization, for example, within the nervous system87. 
Developing small molecules that can inhibit RGS protein/Gα binding have been proposed as 
molecular targets to potentiate the actions of endogenous neurotransmitters in a multitude of 
disease states such as Alzheimer’s disease, depression, and epilepsy89. Also, targeting RGS 
proteins has been proposed to boost efficacy of current GPCR-directed drugs while decreasing 
the therapeutic dose in order minimize adverse side effects89. Targeting RGS proteins have 
also been proposed to decrease tolerance and possibly reduce desensitization to agonist drugs. 
For example, opioid tolerance depends on GRK-mediated phosphorylation of agonist-bound 
receptor and binding of arrestin. RGS inhibitors should also reduce desensitization and 
tolerance by reducing the fractional receptor occupancy that is required for an analgesic 
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effect89. Currently, these are proposed outcomes of RGS protein drug targeting. If the 
physiological and pathophysiological roles of RGS proteins are well-established, then targeting 
RGS proteins could become a viable pharmacological approach in animal studies and human 
diseases. 
1.2.7 OVERVIEW OF RGS2 
The R4/B subfamily of RGS proteins contain ten members including, RGS1-5, RGS8, RGS13, 
RGS16, RGS18, and RGS21. The R4/B subfamily contain the smallest RGS proteins, 
containing relatively short peptide sequences (2-80 amino acids) flanking the N- and C-
terminal ends of the RGS domain, with just one exception (RGS3)90. RGS3 exists as several 
isoforms that are all splice variants from the RGS3 gene. The shortest splice variant contains 
little more than the RGS domain, synonymous with the other R4/B subfamily, whereas the 
longer isoforms may contain PDZ, PEST, and/or acidic domains90. PDZ domains are protein-
protein interaction domains that are specialized for binding to short peptide motifs at the 
extreme carboxy termini of other proteins, although they can have other modes of action91. A 
PEST domain is rich in proline (P), glutamic acid (E), serine (S), and threonine (T), which is 
associated with proteins that have a short intracellular half-life92. 
RGS2, the focus of this thesis, is unique among the RGS protein family. RGS2 is a 211 amino 
acid protein that contains an ~120 amino acid conserved RGS domain between residues 80-
205 that mediates it GAP activity93. RGS2 also contains four initiator methionine residues at 
positions 1, 5, 16, and 33, any of which can initiate protein production in mammals94 (Figure 
1.4). RGS2 is found ubiquitously throughout the body72,95–100, which allows it to play an 
important role in many physiological processes. Indeed, RGS2 appears to play an important  
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Fig 1.4. Representative RGS2 protein with the first 40 amino acids. The RGS domain is 
located between amino acids 80 and 205. Alternate start sites (initiation variants) are 
highlighted in red. Point substitutions are highlighted in blue.  
 
 
 
 
20 
 
 
 
role in pathophysiological conditions such as hypertension101–103, anxiety104, aggression75, and 
oxidative stress105. RGS2 is upregulated by Gαs- and Gαq/11-mediated signals, which appear to 
cause cross-desensitization between the pathways106. RGS2 is also upregulated by factors such 
as heat-shock105, electrical stimulation107, ischemia108, and other cellular stress inducing 
agents. Interestingly, other stress related proteins (such as ATF4) are upregulated by cellular 
stress and also contain multiple initiation sites, similar to that of RGS2. Hence, RGS2 may 
have multiple sites of initiation in order to synthesize important isoforms of the protein during 
stressful cellular conditions. 
While RGS4, another R4/B subfamily member, possesses good GAP activity for Gαi/o and 
Gαq/11, RGS2 lacks in vitro GAP activity for Gαi/o, but has been reported to be quite potent in 
blocking Gαq/11-directed activation of PLC-β93. The structural basis for RGS2’s poor GAP 
activity for Gαi/o compared to RGS4 is thought to be due to a three amino acid substitutions in 
the Gα binding surface of RGS293,109. It is suggested that these structural differences in RGS2 
may impair the binding of RGS2 to Gαi/o but in theory could favour the binding to Gαq/1193. An 
important factor in the binding of RGS2 to Gα proteins is plasma membrane targeting. 
Truncation of the first 78 amino acids (N-terminus) of RGS2 results in the loss of effector 
antagonism of RGS2 but not its GAP activity, suggesting that the N-terminus may have a 
plasma membrane targeting function93,110.  
RGS2 also has the ability to inhibit Gαs pathways. The structural basis for its inhibitory effects 
remains unknown and controversial as to whether RGS2 binds Gαs, isoforms of adenylyl 
cyclase, or both. When purified recombinant RGS2 was added to purified recombinant 
adenylyl cyclase V cytoplasmic domains, it was able to decrease cAMP production stimulated 
by either Gαs or by forskolin111. However, others have demonstrated that RGS2 protein can be  
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immunoprecipitated with purified Gαs112. Additionally, RGS2 is recruited to the plasma 
membrane when co-expressed with Gαs and when RGS2 is co-expressed with isoforms of 
adenylyl cyclase11. Regardless of how RGS2 inhibits Gαs, this function of RGS2 is important 
in many physiological processes including the olfactory system. Addition of recombinant 
RGS2 to olfactory epithelia membranes blocked odorant-induced cAMP production 
suggesting that RGS2 negatively regulates Gαs-mediated pathways, as Gαolf belongs to the 
Gαs-family93.  
RGS2 is interesting in that it can have numerous SNPs, several of which can affect its 
regulation and function84,86 (Figure 1.4). One point mutation, RGS2 M5V, is found within a 
Japanese population of hypertensive patients, but it was not identified in healthy control 
patients86. Another point mutation, RGS2 G23D, has been associated with a phenotypic patient 
profile that includes borderline IQ, hirsutism, upregulation of bone alkaline phosphatase due 
to an increase in bone mass, and decreased platelet Gαs function leading to enlarged, round 
platelets with abnormal α-granules84. The authors concluded that the genetic defect in RGS2 
causes a preference for translation via the first two initiator methionine residues at amino acid 
positions 1 and 5, rather than 16 and 33, to initiate protein production.  
Within the larger two forms of RGS2 is a putative adenylyl cyclase binding domain (amino 
acids 9-11), which is absent in the two shorter forms of RGS284. Therefore, if the altered 
genetic sequence of RGS2 G23D is causing a shift towards production of the longer forms of 
RGS2, Gαs signaling may be inhibited more strongly, resulting in the pathological conditions 
seen in patients84. The mechanism as to how these pathophysiological conditions occur remains 
controversial as it is still unclear if RGS2 in fact directly binds to all forms of adenylyl 
cyclase11.  
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Mice lacking RGS2 have previously been shown to spontaneously develop hypertension and 
cardiac hypertrophy and this correlates with decreased attenuation of Gαq/11 signaling113. 
Authors concluded that it could also be due to altered kidney function114 and increased 
circulating catecholamines115. This has led us to hypothesize RGS2 M5V may not be attenuate 
Gαq/11 signaling as well as wild-type RGS2, thus potentially leading to hypertension86. By 
looking at the phenotypic profile of a RGS2 G23D patient, it was shown that there is a 
decreased platelet Gαs function, suggesting that this mutant will attenuate Gαs-linked GPCR 
signaling to a greater degree than wild-type RGS2 protein. There are two RGS2 SNPs without 
any known pathophysiological effects but are found in between the RGS2 M5V and RGS2 
G23D mutations; RGS2 R14I and RGS2 K18N. Although there is little known about these 
mutations, RGS2 R14I is close to, but is not part of the putative adenylyl cyclase binding region 
at amino acids 9-11. RGS2 K18N also contains a SNP between the RGS2 M5V and RGS2 
G23D SNPs, and appears to not play a role in hypertension85. Currently, it is unknown if and 
how the mutations affect Gα signaling, but we hypothesize that these RGS2 SNPs may affect 
the stability of the protein, thus influencing Gα signal attenuation. 
1.3 KINETIC REGULATION OF G PROTEIN ACTIVITY 
To understand how G protein-mediated signaling occurs, the kinetics of G protein activation 
and deactivation must first be understood. The first step in the G protein activation/deactivation 
cycle is GDP dissociation. The relatively high concentration of GTP in a cell (while free GDP 
is relatively low) leads to a rapid association of GTP after GDP dissociation30. Thus, the rate 
of nucleotide exchange depends highly on the rate of GDP dissociation. GTP dissociation is 
relatively slow and as a result, GTP is normally hydrolyzed by the G protein even before it 
dissociates30. Overall, nucleotide exchange and GTP hydrolysis are two key reactions that 
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determine the duration of G protein signaling30. As alluded to in section 1.1.1, the kinetics of 
G protein signaling are tightly regulated by GEFs, GDIs, and GAPs, and the delicate balance 
among these regulatory mechanisms can affect the rate and magnitude of G protein signaling. 
1.3.1 GEF-MEDIATED ACTIVATION OF G PROTEINS 
From a kinetic point of view, the fractional activation of the G protein reflects the balance 
between GEF-promoted activation and GAP promoted deactivation116. GEFs, such as GPCRs, 
dramatically increase the rate of GDP dissociation, resulting in an increase in GTP association 
and ultimately, G protein activation.  
An interesting non-receptor G protein activator is Ric-8 (resistance to inhibitors of 
cholinesterase 8A), which shares similar but not identical mechanism with that of the GPCR. 
Ric-8 favours binding with high affinity to the open conformation of the G protein thus, the 
effect of Ric-8 on fractional activation of G protein may be nucleotide concentration 
dependent116. Ric-8 also promotes the dissociation of both GDP and GTP which, at lower 
concentrations of GTP (< 500 nM), helps to reduce GTP turnover116. At higher GTP 
concentrations, as are found intracellularly (~150 μM), GTP association is greater than 
dissociation and the Gα-GTP form predominates116. Ric-8 has also been reported to increase 
cellular G protein levels by stabilizing G proteins in a nucleotide-free conformation thus 
preventing denaturation117. This finding has profound implications with respect to Gαq/11 
activation kinetics as Gαq/11 tends to have a fast denaturation rate when in the nucleotide-free 
state118. As the binding of GTP competes with the denaturation of ligand-free Gαq/11, increasing 
the concentration of GTP decreases denaturation and thus enables the formation of Gαq/11-GTP. 
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The fact that Ric-8 is able to decrease the denaturation rate of the G protein will further benefit 
the formation of the active GTP-bound G protein.  
1.3.2 GDI-MEDIATED INHIBITION OF G PROTEIN ACTIVATION  
Nucleotide exchange is intrinsically limited by the relatively slow rate of nucleotide 
dissociation. GDI activity, which decreases the GDP dissociation, may also lead to an overall 
reduction in G protein activation. Among the GDIs identified for heterotrimeric G proteins, the 
best studied proteins are those containing the GoLoco motif (also called GPR domain and 
GPSM domain) – a highly conserved 19 amino acid motif119 that has a much higher binding 
affinity for GDP-bound Gα relative to either nucleotide-free or GTP-bound Gα120. It has been 
shown that the rate of GTPγS binding, which reflects nucleotide exchange, is decreased up to 
80% in the presence of GoLoco proteins or peptide derived from the GoLoco motifs of RGS12 
and RGS14121,122. The function of GoLoco motifs becomes more complicated by its propensity 
to compete with Gβγ in binding to Gα. The Gβγ dimer is also able to slow down the rate of 
intrinsic GDP dissociation from the Gα subunit up to 50 fold, depending on the specific G 
protein in question123. Notwithstanding this, Gβγ is necessary for receptor-stimulated Gα 
activation since it can stabilize Gα-receptor coupling. 
1.3.3 GAP-MEDIATED GTP HYDROLYSIS 
The GTP hydrolysis rate of proteins can be increased up to 2000 fold by GAPs such as RGS 
proteins124. As a result, RGS proteins negatively regulate the G protein cycle by both 
dampening signaling output and by rapidly terminating G protein activation upon removal of 
a stimulus124. Interestingly, kinetic characterization indicated that the rate of the overall steady-
state GTPase reaction measured in the presence of PLC-β is 10 times faster than the rate of 
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GTP binding to G protein in the absence of PLC-β125. Moreover, even though the GTP 
hydrolysis is dramatically increased by GAPs, the fact that the fractional activation of G protein 
still remains high suggests that either the activation rate is also increased or the GAP activity 
is inhibited while the receptor is activated.  
One theory that supports the idea that RGS proteins are able to potentiate receptor-mediated G 
protein activation is a proposed kinetic scaffolding mechanism125,126. In this model, GAPs are 
able to reduce depletion of local Gα-GDP levels to permit rapid recoupling to receptor and 
sustained G protein activation. In combination with the kinetic scaffolding mechanism, there 
is another model based on the idea of physical scaffolds. This model suggests that RGS proteins 
may directly or indirectly interact with the receptor and facilitate receptor-G protein coupling 
and promote signal onset thus, RGS proteins may act as a scaffold to assemble different 
signaling components127. The theories described provide insights into how G protein signaling 
is regulated by different factors. It is prudent to understand how the mechanisms are regulated 
themselves, whether it be due to transcriptional differences in the mechanisms or alterations in 
protein levels. 
1.4 PROTEIN DEGRADATION 
The half-life of a protein depends on how rapidly it is produced and degraded. The majority of 
proteins are degraded in a selective protein ubiquitin-proteasomal fashion which depends on 
three classes of enzymes; E1, E2, and E3128. E1 enzymes attach an ATP to ubiquitin, E2 
enzymes are ubiquitin-conjugating enzymes, and E3 are ubiquitin-ligase enzymes bind E2 
enzymes and the target protein to mediate ubiquitination; this cycle repeats itself until the 
ubiquitinated proteins are recognized and the protein is ultimately degraded by the 
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proteasome128. Selective protein turnover results in protein levels that can rapidly change in 
response to external stimuli that alter degradation rates. Furthermore, abnormal products, such 
as misfolded proteins, can be rapidly degraded128. Long lived proteins typically are degraded 
by the lysosomal pathway, which is a non-selective pathway129. It is often assumed that 
lysosomal degradation is only for degrading endocytosed particles, but endogenous proteins 
also have the ability to bind to the lysosomal membrane, which controls the rate of entry into 
the lysosome and subsequent degradation of the protein129. This process is relatively slow 
compared to the rapid ubiquitin-proteasome pathway, which is why it is thought that only long 
lived proteins are degraded via the lysosomal pathway129. RGS proteins, specifically RGS4 
and RGS5, have previously been shown to be degraded by the ubiquitin-proteasome pathway, 
and their rapid degradation was attributed to the presence of specific amino acids within their 
N-termini130,131. 
1.4.1 N-END RULE PATHWAY 
In 1986, Alexander Varshavsky and co-workers developed the N-end rule which proposes that 
the N-terminal amino acid of a protein determines its half-life or likelihood of being 
degraded132 (Figure 1.5). Specific amino acids within the N-termini, called N-degrons, present 
degradation signals that may promote the rapid breakdown of proteins131,133. The idea behind 
the N-end rule is that degrons on short-lived proteins in eukaryotes are recognized by ubiquitin 
ligases, which mediate the conjugation of ubiquitin to an internal lysine residue of the substrate, 
resulting in the ATP-dependent degradation by the 26S proteasome128,130,133,134.  
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Fig. 1.5. The classical N end rule pathway. Tertiary destabilizing residues asparagine and 
glutamine are, respectively, deamidated into secondary destabilizing residues aspartic acid and 
glutamic acid by NTAN NtN-amidase and NTAQ NtQ-amidase, which are in turn arginylated 
by ATE1-encoded arginyl (R)-transferase isoforms generating the degron arginine. N terminal 
cysteine is converted to a substrate of arginylation through its oxidation. N terminal arginine, 
as well as type 1 and type 2 residues, are recognized and bound by the N-recognin family 
members, which mediate ubiquitylation and proteasomal degradation, via detection by the 
UBR box. Adapted from Tasaki et al., 2012, with permission134. 
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1.4.2 RECOGNITION OF N-DEGRONS  
The recognition of N-degrons is mediated by N-recognins which induce protein ubiquitylation 
and proteolysis via the proteasome. The mechanism of substrate selectivity was revealed by 
the discovery that the UBR box, conserved in many N-recognins, is the substrate recognition 
domain135,136. The mammalian genome encodes seven known UBR box proteins, UBR1-
UBR7, which all contain signature substrate recognition components of the ubiquitin-
proteasome system, with exception of UBR4134. UBR1-UBR3 are referred to as canonical due 
to their sequence homology, size (~200 kDa), and conserved domains including the UBR box 
(type 1 binding site), N domain (type 2 binding site), RING finger (ubiquitinylation domain), 
and autoinhibitory domain (which sterically blocks the UBR box and N domain)134. UBR4-
UBR7 are referred to as non-canonical UBR box proteins as they are non-sequelogous to one 
another134.  
The recognition of N-end rule substrates initiates with hydrogen bonding with the free α-amino 
group of the N-terminal residue134. Once engaged, N-recognin establishes a substrate-selective 
interaction through hydrogen bonds with the positively charged side chains. Overall, N-end 
rule interactions are largely confined to the first two residues, enabling N-recognins to select 
substrates on the basis of destabilizing N-terminal residues137,138. UBR1 and UBR2 also have 
a second substrate-binding domain, the N domain, which binds to type 2 degrons (Figure 
1.5)139.  
1.4.3 UBIQUITIN ACTIVATION AND CONJUGATION  
Ubiquitin can be activated by two ubiquitin-activating enzymes (E1), UBA1 and UBA6140. 
UBA1 is the major E1 ubiquitin-activating enzyme responsible for the bulk of ubiquitin  
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conjugation to E2 enzymes, whereas UBA6 is an alternate E1 enzyme with a designated E2 
enzyme, USE1140. Though UBA1 is used more often, it has been shown that mice lacking 
UBA6 die in utero, suggesting that UBA6 plays an essential role in mammalian 
development141. Recently, it has been shown that UBA6 mediates the ubiquitin activation and 
conjugation for the canonical N-recognins, UBR1-UBR3, and one substrate of UBA6-
activated N-recognins includes RGS4142. Once ubiquitin has been activated by E1 enzymes, 
the ubiquitin molecule is transferred to a member of the ubiquitin-conjugating enzymes (E2). 
This transfer forms a thioester-charged E2 intermediate that can associate with an E3 ubiquitin-
ligase enzyme to promote ubiquitin transfer from the E2 to the substrate of interest and 
ultimately lead to degradation142.  
1.4.4 RGS PROTEINS AND THE N END RULE 
Although all proteins are not intrinsically unstable, they may become so via N-arginylation or 
the substitution of an amino acid for a destabilizing arginine residue130. RGS4 and RGS5 are 
two proteins known to undergo N-arginylation and ultimately follow the ubiquitin-proteasome 
degradation pathway131. Both RGS4 and RGS5 have a conserved N-terminal  
cysteine at amino acid position 2130, and cysteine is known to undergo N-arginylation131. After 
mutating the N-terminal cysteine of RGS4 and RGS5 to a serine, these proteins were no longer 
found to be rapidly degraded, suggesting that rapid degradation of RGS4 and RGS5 was reliant 
on the conserved cysteine130. An N terminal cysteine is rapidly oxidized after the removal of 
the initiator methionine (by a methionine aminopeptidase), which results in a pre-N-degron 
protein, allowing arginylation to occur by ATE1-encoded Arg-transferase131. An N-terminal 
arginine allows E3 enzymes (ubiquitin-protein ligase E3 component n-recognin 1 and 2, or 
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UBR1 and UBR2) to recognize the amino acid, and thus ubiquitin can be added to the protein. 
Further additions of ubiquitin ultimately result in degradation of the protein143. The 
physiological importance of protein arginylation has been established by the discovery that 
ATE1-deficient mouse embryos die due to cardiac and vascular development abnormalities134.  
The rapid ubiquitin-proteasome degradation caused by the conserved cysteine residues of 
RGS4 and RGS5 has also been reported to occur when there is a conserved glutamine or 
asparagine residue at amino acid position 2131. The mechanism to generate N-degrons from a 
glutamine or asparagine differs from that involving a conserved cysteine. Instead of oxidation, 
glutamine and asparagine residues undergo deamidation134. Deamidation is a chemical reaction 
in which an amide functional group is removed or replaced. N-terminal glutamine and 
asparagine are respectively deamidated by NTAQ1-encoded NtQ-amidase and NTAN1-
encoded NtN-amidase, which are not analogous to each other134. The physiological function of 
deamidation was initially identified in NTAN1-deficient mice who were found to exhibit 
impaired memory, learning, and social behaviour which appeared to be primarily due to 
dysregulation of proteasomal degradation of the microtubule-associated protein 2 in the 
hippocampal neurons134. Glutamine and asparagine are respectively deamidated into the 
secondary destabilizing residues glutamic acid and aspartic acid, which are in turn arginylated 
by ATE1-encoded arginyl (R)-transferase isoforms generating the degron arginine and 
continuing on with degradation of the protein134. Although this process has not been reported 
in RGS2, which has a conserved glutamine at amino acid position 2, it is plausible that RGS2 
protein may also be rapidly ubiquitinated and degraded in a similar fashion to RGS4 and RGS5. 
There is evidence that RGS2 is rapidly ubiquitinated and degraded. When HEK293 cells were 
transiently transfected with RGS2 and HA-ubiquitin, they were shown to co-
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immunoprecipitate together and to a greater extent in the presence of the proteasome inhibitor 
MG132144. Also, since mutations in the N-terminal domains of RGS4 and RGS5 lead to altered 
degradation rates130, it is possible that RGS2 SNPs may also have altered degradation rates 
compared to the wild-type RGS protein. 
1.5 RESEARCH GOALS AND SIGNIFICANCE 
RGS proteins, specifically RGS4 and RGS5, appear to be rapidly turned over unless there are 
specific mutations within the N-terminus130. Slight variations in the rapid turnover of RGS 
proteins can affect the way GPCR signals are attenuated. For instance, if the presence of RGS2 
within a cell was increased or decreased from basal levels, this would be expected to cause 
GPCR signaling to be decreased or increased, respectively. In this study, our principal goal 
was to examine the molecular mechanisms controlling the degradation of RGS2. These studies 
were done in cellular in vitro models to establish a basic understanding of what is potentially 
occurring at the molecular level. Our major goals were as follows: 
i. To determine the stability of wild-type and mutant forms of RGS2 (Study A) 
ii. To determine the effects of wild-type and mutant forms of RGS2 on G protein-
mediated signaling (Study B) 
1.5.1 STUDY A: STABILITY OF WILD-TYPE AND MUTANT FORMS OF RGS2 IN 
VITRO 
Regardless of the anticipated function of a protein, if it is targeted for degradation before it can 
perform its task, it can be rendered useless. Evidence in our lab has shown that wild-type RGS2 
is a rapidly degraded protein. Here we report that the use of alternative initiator methionine 
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residues alters the half-life of RGS2. Furthermore, mutations within the N-terminus of RGS2 
also have severe effects on the half-life. We also provide evidence that RGS2 is degraded via 
the ubiquitin-proteasome pathway. However, the degree to which expression levels change 
depend on which initiator methionine is used or if RGS2 contains a SNP. 
The objectives in this study were to: 
1) Determine the effects of different methionine initiation sites and N-terminal 
mutants on RGS2 stability 
2) Determine the effects of inhibitors of degradation on RGS2 expression levels  
1.5.2 STUDY B: EFFECTS OF WILD-TYPE AND MUTANT FORMS OF RGS2 ON Gαq/11 
SIGNALING 
RGS2 is known to attenuate Gαq/11 signaling but the degree to which each initiation variant can 
inhibit signaling is unknown. Here we report that each initiation variant, as well as each RGS2 
SNP, has an altered ability to attenuate Gαq/11 signaling compared to the full-length wild-type 
RGS2. 
The objective in this study was to: 
1) Determine the effects of RGS2 methionine initiation sites and N-terminal mutants 
on the ability to attenuate Gαq/11 signaling 
Based on the results presented here, we propose that RGS2 is a rapidly degraded protein that 
is usually degraded via the ubiquitin-proteasomal pathway. Which initiator methionine initiates 
translation can have profound effects on the half-life of the protein and also the ability to 
attenuate Gαq/11 signaling. Also, mutations within the N-terminus of RGS2 can alter the 
protein’s half-life and ability to attenuate Gαq/11 signaling. Understanding the molecular 
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mechanisms behind the regulation of RGS2 may provide insight into why individuals with 
RGS2 mutations show the phenotypic profile they do. 
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2 MATERIALS AND METHODS 
2.1 CELL LINE 
In vitro based studies using the well-established Human Embryonic Kidney 293 (HEK293) 
cell line were used to assess how RGS2 is regulated. HEK293 cells are commonly used for in 
vitro experiments due to their ease of transient transfection1. HEK293 cells were maintained 
in Dulbecco’s Modified Eagle Medium (DMEM, Gibco Life Technologies) supplemented with 
10% Fetal Bovine Serum (FBS, Gibco Life Technologies) at 37ºC with 5% CO2. Cells were 
seeded every 48 or 72 h at a density of 2.2x106 or 0.8x106 cells, respectively, in 10 ml medium 
in a 10 cm dish. Seeding density into smaller dishes were calculated depending on the surface 
area (cm2) of the plate. 
2.2  DNA CONSTRUCTS 
A mammalian expression vector encoding full-length, C-terminally FLAG-tagged, wild-type 
RGS2 in pcDNA3.1+ (Figure 2.1) was custom generated by the University of Missouri-Rolla 
cDNA Resource Center (www.cdna.org). Mutant constructs derived from the initial plasmid 
were generated in our laboratory. RGS2 M5V, RGS2 R14I, RGS2 K18N, and RGS2 G23D 
were generated by performing QuikChange site-directed mutagenesis according to the 
manufacturer’s protocol (Agilent, 200522). tM5 RGS2, tM16 RGS2, tM33 RGS2, RGS2 M5V, 
RGS2 R14I, RGS2 K18N, and RGS2 G23D (Table 2.1) were amplified by polymerase chain 
reaction (PCR) as Kpn1-Eco81I fragments in which the primers introduced the mutations. 
Primers (Table 2.2) introduced a pseudo-Kozak sequence in the full length wild-type RGS2, 
tM5 RGS2, tM16 RGS2, and tM33 RGS2. Plasmid DNA was purified using Qiagen Plasmid 
Maxi Kit (Qiagen, 12163). FLAG-tagged 5-HTAR was a gift from Dr. Stephen Ferguson,  
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Figure 2.1. Full-length wild-type RGS2 construct.  
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Table 2.1. Amino acid sequence of RGS2 constructs 
 
First 40 amino acids of RGS2 constructs with initiator methionines and mutations 
FL-WT RGS2 MQSAMFLAVQ HDCRPMDKSA GSGHKSEEKR EKMKRTLLKD 
tM5 RGS2 MFLAVQHDCR PMDKSAGSGH KSEEKREKMK RTLLKDWKTR 
tM16 RGS2 MDKSAGSGHK SEEKREKMKR TLLKDWKTRL SYLFQNSSTP 
tM33 RGS2 MKRTLLKDWK TRLSYFLQNS STPGKPKTGK KSKQQAFIKP 
RGS2 M5V MQSAVFLAVQ HDCRPMDKSA GSGHKSEEKR EKMKRTLLKD 
RGS2 R14I MQSAMFLAVQ HDCIPMDKSA GSGHKSEEKR EKMKRTLLKD 
RGS2 K18N MQSAMFLAVQ HDCRPMDNSA GSGHKSEEKR EKMKRTLLKD 
RGS2 G23D MQSAMFLAVQ HDCRPMDKSA GSDHKSEEKR EKMKRTLLKD 
 
The first 40 amino acid residues for RGS2 constructs. Alternate start sites (initiation variants) 
are highlighted in red. Point substitutions are highlighted in blue. 
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Table 2.2. Primers for making wild-type RGS2 and its mutants 
 
Construct 5’ primer 3’ primer 
FL-WT RGS2 ACTAGTGGATCCGCCACCATGGCGCAAAGTGCTA
TGTTCTTG 
ACCGGTCGGTTCAAGTCTTCTTCTGA 
tM5 RGS2 ACTAGTGGATCCGCCACCATGGCGTTCTGGCTGT
TCAACAC 
ACCGGTCGGTTCAAGTCTTCTTCTGA 
tM16 RGS2 ACTAGTGGATCCGCCACCATGGCGGACAAGAGC
GCAGGCAGT 
ACCGGTCGGTTCAAGTCTTCTTCTGA 
tM33 RGS2 ACTAGTGGATCCGCCACCATGGCGAAACGGACCC
TTTTAAAAGATTGG 
ACCGGTCGGTTCAAGTCTTCTTCTGA 
RGS2 M5V ACCATGCAAAGTGCTGTGTTCTTGGCTGTTC GAACAGCCAAGAACACAGCACTTTGCATGGT 
RGS2 R14I TTCAACACGACTGCATACCCATGGACAAGAG CTCTTGTCCATGGGTATGCAGTCGTGTTGAA 
RGS2 K18N CAGACCCATGGACAACAGCGCAGGCAGTGGC GCCACTGCCTGCGCTGTTGTCCATGGGTCTG 
RGS2 G23D AGAGCGCAGGCAGTGACCACAAGAGCGAGGA TCCTCGCTCTTGTGGTCACTGCCTGCGCTCT 
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University of Western Ontario2. All sequences were confirmed using Robarts Research 
Institute DNA Sequencing Facility. 
2.3  TRANSFECTION 
For immunoblotting, HEK293 cells were cultured in a 12-well plate under standard conditions 
of 37ºC and 5% CO2, in DMEM with 10% FBS and transient transfections were performed 
using Lipofectamine 2000 (Life Technologies, 11668-019) according to the manufacturer’s 
protocol. To summarize the protocol, cells were seeded and grown to 70% confluence before 
transfection. Once 70% confluent, 4 μl of Lipofectamine 2000 reagent was diluted into 100 μl 
of Opti-MEM® I Reduced Serum Medium (Life Technologies, 31985-070) in an Eppendorf 
tube. 1 μg plasmid DNA was diluted in a separate tube containing 100 μl of Opti-MEM® I 
Reduced Serum Medium and both tubes were incubated at room temperature for 5 min. The 
tubes were thoroughly mixed together and were incubated at room temperature for 20 min. The 
combined mixture was added to the cells and allowed to incorporate into the cells for 24 h.  
For inositol-phosphate turnover experiments, HEK293 cells were transiently transfected in 
suspension and seeded in a 24-well plate. Briefly, 10 μl of Lipofectamine 2000 reagent was 
diluted into 250 μl of Opti-MEM® I Reduced Serum Medium in an Eppendorf tube. 2 μg 5-
HT2AR plasmid DNA and either 2 μg RGS2 plasmid DNA or 2 μg pcDNA3.1+ DNA was 
diluted in a separate tube containing 250 μl of Opti-MEM® I Reduced Serum Medium and 
both tubes were incubated at room temperature for 5 min. The tubes were mixed thoroughly 
together and were incubated at room temperature for 20 min. HEK293 cells from a 70% 
confluent 10 cm plate were sedimented, mixed with 20 ml of fresh DMEM with 10% FBS and 
the combined mixture of Opti-MEM®, Lipofectamine 2000, and plasmid DNA were added to 
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the cells. Cells were seeded at 0.1 x 106 cells per well of a 24-well plate and were allowed to 
incorporate into DNA for 24 h.  
2.4  DRUG TREATMENT 
24 h post-transfection, cells were treated with well-established pharmacological agents to 
either inhibit proteasomal degradation or to attenuate global protein synthesis. HEK293 cells 
were subjected to MG-132 (Sigma-Aldrich, M7449-200UL) (20 μM) treatment (2 h) in order 
to inhibit the ubiquitin-proteasome pathway3. This was performed in parallel with 0.05% 
DMSO (Fisher Scientific, D128-500) vehicle controls. HEK293 cells were subject to 
cycloheximide (Sigma-Aldrich, C4859-1ML) (CHX, 20 μM) treatment over a period of 320 
min in order to attenuate protein synthesis at varying times4. This was performed in parallel 
with 0.05% DMSO vehicle controls. 
2.5  PROTEIN ISOLATION 
Cell lysates were prepared by washing twice with ice-cold 1X phosphate-buffered saline (PBS, 
Fisher Scientific, BP399-4) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, pH 7.4) and 
scraped into 150 μl of ice-cold lysis buffer (250 mM NaCl, 50 mM Tris pH 8, 5 mM EDTA, 
0.5% NP-40 (IGEPAL), phenylmethylsulfonyl fluoride protease inhibitor tablet (Roche, 
04693116001), 20 mM Na4P2O7, 10 mM NaF, and 20 mM Na3VO4). Cell lysates were 
homogenized by vigorous pipetting and underwent three consecutive freeze-thaw cycles via 
flash freezing with liquid nitrogen. Pellets were sedimented by centrifugation at 11 000 x g for 
15 min at 4ºC. Supernatants were collected and protein concentrations were determined using 
Bradford Protein Assay (Bio-Rad, 500-0006).  
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2.6  IMMUNOBLOTTING 
Protein samples were prepared in 5X Laemmli loading (sample) buffer (60 mM Tris-HCl pH 
6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.02% bromophenol blue) and balanced 
with 1X sample buffer for equal protein concentration. Samples were heated at 99ºC for 5 min 
prior to gel loading and gel electrophoresis in order to denature the proteins. Equal amounts of 
protein (20 μg) were separated by 12% SDS-PAGE and wet transferred onto PVDF membrane 
(Millipore, IPVH00010). Membranes were incubated for 1 h in blocking buffer (Tris-buffered 
saline, 0.1% Tween 20, 5% skim milk) and rocked at room temperature before overnight 
incubation at 4ºC, rocking with either: anti-FLAG (1:1000, Sigma F3165) or anti-β tubulin for 
protein loading control (1:1000, Pierce PA5-16863). Following overnight incubation, 
membranes were washed 4 times for 5 min with TBST (Tris-buffered saline, 0.1% Tween 20) 
and incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary 
antibodies: anti-mouse IgG (1:5000, Pierce 31168) or anti-rabbit IgG (1:5000, Pierce 31463). 
Immunoblots were then washed 4 times for 5 min with TBST. Immunoblots were visualized 
with SuperSignal West Pico chemiluminescent substrate (Thermo Scientific, 34080) and 
digitally imaged using Bio-Rad VersaDoc camera and Quantity One program (Bio-Rad, model 
GS-700).  
2.7 INOSITOL-PHOSPHATE TURNOVER 
HEK293 cells were seeded in 24-well plates and transiently transfected with 5-HT2AR and 
RGS2 plasmids as described in section 2.3 and the figure legends. Experiments were performed 
according to previous protocols2,5. 24 h post-transfection, cells were incubated overnight in 
500 μl serum-free DMEM with 1 μCi/ml myo-[3H]-inositol (PerkinElmer, NET1168001MC). 
For all experiments, cells were incubated for 1 h in Hank’s Balance Salt Solution (HBSS –Life 
53 
 
 
 
Technologies, 14025-092) (1.3 mM CaCl2, 0.5 mM MgCl2, 0.4 mM MgSO4, 5.3 mM KCl, 
0.44 mM KH2PO4, 4.2 mM NaHCO3, 138 mM NaCl, 0.34 mM Na2HPO4, and 5.6 mM D-
glucose) and were then incubated at 37ºC with 5% CO2 with 500 μl of 10 mM LiCl alone for 
10 min followed by increasing doses of serotonin hydrochloride (Sigma-Aldrich, H9523-
25MG) in 500 μl 10 mM LiCl for 30 min. Cells were placed on ice and the reaction was stopped 
with 500 μl of 0.8 M perchloric acid and was neutralized with 400 μl of 0.72 M KOH, 0.6 M 
KHCO3 overnight in 4ºC. Total cellular [
3H]-inositol incorporation was determined in 50 μl of 
cell lysate with 5 ml EcoLite(+)TM Liquid Scintillation Cocktail (MP Biomedicals, 
0188247504). Total inositol phosphate was purified with 4 ml 0.1 M formic acid / 1 M 
ammonium formate by anion exchange chromatography using 2 ml Dowex 1-X8 (formate 
form) 200-400 mesh anion exchange resin6 (BioRad, 140-1454) after two consecutive 5 mL 
water and 60 mM ammonium formate washes. [3H]-inositol phosphate formation was 
determined by liquid scintillation in 15 ml EcoLite(+)TM Liquid Scintillation Cocktail using a 
Beckman LS 5500 scintillation system and calculations are shown below. 
2.8 DENSITOMETRY AND STATISTICAL ANALYSIS 
Immunoblots for MG132 experiments were analyzed using densitometry software (Quantity 
One, Bio-Rad) and expression levels were normalized to β-tubulin expression levels. Group 
data are presented as means ±SEM. Data were compared by two-way analysis of variance 
(ANOVA) and were further evaluated by Bonferroni post-test. Statistical analyses were 
performed using GraphPad Prism® 5.0 and p-values of <0.05 were considered statistically 
significant. 
Immunoblots for CHX experiments were analyzed using Quantity One and expression levels 
were normalized to β-tubulin expression levels. RGS2 protein (relative to β-tubulin) at each 
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time point was normalized to the corresponding 0 time point. Group data are presented as 
means ± SEM and are fit according to the one phase decay equation.  
Y=(Yo – plateau)-kx + plateau 
Statistical analyses were performed using GraphPad Prism® 5.0. 
Percent conversion of [3H]-inositol to [3H]-inositol phosphates were solved using:  
(DPM from column)(1.2/0.8) / (DPM in 50 μl)(1.2/0.05) 
Where 1.2 = total neutralized cell extract (ml), 0.8 = 800 μl placed into the column, and 0.05 
= 50 μl control cell extract. The data are representative of the mean ± SEM of three independent 
experiments normalized to the largest value of 5-HT2AR + pcDNA3.1
+ within the data set. Each 
graph is representative of experiments done simultaneously. Thus, 5-HT2AR + pcDNA3.1
+ and 
5-HT2AR + FL-WT RGS2 experiments were performed with the corresponding conditions in 
each of the graphs. Dose-response curves were fit by using nonlinear regression specifically 
the sigmodal dose-response equation was used: 
Y = Bottom + (Top-Bottom) / (1 + 10logEC50-x) 
This equation is also referred to as a three-parameter logistic equation. The bottom value of 
each graph was constrained to a common value for all data sets. EC50 values were compared 
by one-way analysis of variance (ANOVA) and were further evaluated by Bonferroni post-
test. All analyses were performed using GraphPad Prism® 5.0. 
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3 RESULTS 
3.1  STABILITY OF WILD-TYPE AND MUTANT FORMS OF RGS2 IN VITRO 
Due to the importance of RGS2 within a cell, we were particularly interested in determining 
the half-life of full-length wild-type RGS2 as well as the half-lives of different point mutations 
and alternative initiation variants. Differences in the half-lives of various RGS2 constructs 
compared to the full-length wild-type form may underlie corresponding differences in GPCR 
signaling levels; a longer RGS2 half-life could result in greater GPCR signal attenuation. 
3.1.1 RGS2 SNPS AFFECT PROTEIN TURNOVER RATE 
Cycloheximide (CHX) is a well-established blocker of translational elongation and thus it acts 
as an inhibitor of protein synthesis1. This property allows for the determination of the half-life 
of a protein of interest1. The half-life of a protein is taken as the time after CHX addition for it 
to be reduced by 50% from baseline levels. Transfected HEK293 cells were treated with CHX 
at different time points, lysed simultaneously, and subject to immunoblotting. RGS2 levels 
were normalized to β-tubulin due to its abundance within a cell and long half-life of ~50 h. 
Full-length wild-type RGS2 was found to have a half-life of 17.7 ± 6.5 min (Figure 3.1). RGS2 
M5V, RGS2 G23D, RGS2 R14I, and RGS2 K18N mutations were found to have half-lives of 
10.3 ± 3.7, 34.7 ± 9.7, 6.3 ± 1.4, and 13.0 ± 4.7 min, respectively (Figure 3.1-Figure 3.5). The 
gray line represents the full-length wild-type RGS2 degradation curve for comparison (Figure 
3.2-3.5). The half-life of full-length wild-type RGS2 is consistent with the findings of a 
previous group who reported it to be 17.5 ± 5.8 min2. Simply by increasing or decreasing the 
turnover time of RGS2 could have significant effects on GPCR signaling. RGS2 M5V 
appeared to have a shorter half-life than full-length wild-type RGS2, which may be why there 
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is a possible association between this SNP and hypertension; Gα signaling is not being 
attenuated to the same degree. In contrast, RGS2 G23D appeared to have a half-life nearly 
double that of the full-length wild-type protein. This suggests that Gα signaling could be 
attenuated more efficiently in someone with this mutation compared to the wild-type RGS2. 
This may explain why individuals with this mutation develop pathophysiological conditions 
synonymous with decreased Gαs signaling. RGS2 R14I had a much shorter half-life than full-
length wild-type RGS2 whereas RGS2 K18N had a similar half-life. Though neither of these 
SNPs is associated with any known phenotype, it would be interesting to screen individuals 
with the RGS2 R14I mutation to see if they have a hypertensive phenotype. The mechanism 
for why we see altered levels due to one point mutation remains unknown. However, it may 
be due to the specific amino acids mutated or located near the mutation affecting degradation 
via the N-end rule. 
3.1.2 RGS2 INITIATION VARIANTS EXHIBIT DIFFERNT PROTEIN TURNOVER 
RATES 
RGS2 contains four different initiator methionine residues, all of which can serve as the points 
for the initiation of translation3. It is important to determine if each initiation variant causes a 
change in half-life compared to the full length wild-type RGS2, as their relative levels could 
conceivably vary depending on cellular conditions4. Unfortunately, we were unable to 
determine the half-life of tM5 RGS2 due to minimal detectability of this protein construct at 
basal levels; this was further exacerbated by CHX treatment (Figure 3.8). tM16 RGS2 and 
tM33 RGS2 had half-lives of 34.5 ± 1.8 and 17.3 ± 4.3 min, respectively (Figure 3.6-Figure 
3.7). These results suggest that tM5 RGS2 is highly unstable intracellularly, and is likely 
degraded at a rate that results in barely measureable protein levels. tM16 RGS2 exhibited 
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Figure 3.1. Full-length wild-type RGS2 degradation curve (A) effect of 20 μM cycloheximide 
(CHX) or vehicle (DMSO) treatment over a period of 320 minutes (n=5). RGS2 protein 
(relative to β-tubulin) at each time point was normalized to the corresponding 0 minute time 
point. The resultant half-life of full-length wild-type RGS2 is 17.7 ± 6.5 minutes. (B) 
Representative immunoblots of full-length wild-type RGS2 after treatment with CHX or 
vehicle. The first panel represents full-length wild-type RGS2 treated with CHX and the second 
panel represents the analogous β-tubulin treated with CHX. The lower two immunoblots 
represent full-length wild-type RGS2 in cells treated with DMSO at 0.05% and cells treated 
with DMSO and probed for β-tubulin. 
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Figure 3.2. RGS2 M5V degradation curve (A) effect of 20 μM cycloheximide (CHX) or 
vehicle (DMSO) treatment over a period of 320 minutes (n=5). RGS2 protein (relative to β-
tubulin) at each time point was normalized to the corresponding 0 minute time point. The 
resultant half-life of RGS2 M5V 10.3 ± 3.7 minutes. The gray line represents full-length wild-
type RGS2 degradation in Figure 3.1. (B) Representative immunoblots of RGS2 M5V after 
treatment with CHX or vehicle. The first panel represents RGS2 M5V treated with CHX and 
the second panel represents the analogous β-tubulin treated with CHX. The lower two 
immunoblots represent RGS2 M5V in cells treated with DMSO at 0.05% and cells treated with 
DMSO and probed for β-tubulin. 
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Figure 3.3. RGS2 G32D degradation curve (A) effect of 20 μM cycloheximide (CHX) or 
vehicle (DMSO) treatment over a period of 320 minutes (n=4). RGS2 protein (relative to β-
tubulin) at each time point was normalized to the corresponding 0 minute time point. The 
resultant half-life of RGS2 G23D 34.7 ± 9.7 minutes. The gray line represents full-length wild-
type RGS2 degradation in Figure 3.1. (B) Representative immunoblots of RGS2 G23D after 
treatment with CHX or vehicle. The first panel represents RGS2 G23D treated with CHX and 
the second panel represents the analogous β-tubulin treated with CHX. The lower two 
immunoblots represent RGS2 G23D in cells treated with DMSO at 0.05% and cells treated 
with DMSO and probed for β-tubulin. 
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Figure 3.4. RGS2 R14I degradation curve (A) effect of 20 μM cycloheximide (CHX) or 
vehicle (DMSO) treatment over a period of 320 minutes (n=4). RGS2 protein (relative to β-
tubulin) at each time point was normalized to the corresponding 0 minute time point. The 
resultant half-life of RGS2 R14I 6.3 ± 1.4 minutes. The gray line represents full-length wild-
type RGS2 degradation in Figure 3.1. (B) Representative immunoblots of RGS2 R14I after 
treatment with CHX or vehicle. The first panel represents RGS2 R14I treated with CHX and 
the second panel represents the analogous β-tubulin treated with CHX. The lower two 
immunoblots represent RGS2 R14I in cells treated with DMSO at 0.05% and cells treated with 
DMSO and probed for β-tubulin. 
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Figure 3.5. RGS2 K18N degradation curve (A) effect of 20 μM cycloheximide (CHX) or 
vehicle (DMSO) treatment over a period of 320 minutes (n=4). RGS2 protein (relative to β-
tubulin) at each time point was normalized to the corresponding 0 minute time point. The 
resultant half-life of RGS2 K18N 13.0 ± 4.7 minutes. The gray line represents full-length wild-
type RGS2 degradation in Figure 3.1. (B) Representative immunoblots of RGS2 K18N after 
treatment with CHX or vehicle. The first panel represents RGS2 K18N treated with CHX and 
the second panel represents the analogous β-tubulin treated with CHX. The following 
immunoblot represents RGS2 K18N in cells treated with DMSO at 0.05% and cells treated 
with DMSO and probed for β-tubulin. 
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Figure 3.6. tM16 RGS2 degradation curve (A) effect of 20 μM cycloheximide (CHX) or 
vehicle (DMSO) treatment over a period of 320 minutes (n=5). RGS2 protein (relative to β-
tubulin) at each time point was normalized to the corresponding 0 minute time point. The 
resultant half-life of tM16 RGS2 34.5 ± 1.8 minutes. The gray line represents full-length wild-
type RGS2 degradation in Figure 3.1. (B) Representative immunoblots of tM16 RGS2 after 
treatment with CHX or vehicle. The first panel represents tM16 RGS2 treated with CHX and 
the second panel represents the analogous β-tubulin treated with CHX. The lower two 
immunoblots represent tM16 RGS2 in cells treated with DMSO at 0.05% and cells treated with 
DMSO and probed for β-tubulin. 
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Figure 3.7. tM33 RGS2 degradation curve (A) effect of 20 μM cycloheximide (CHX) or 
vehicle (DMSO) treatment over a period of 320 minutes (n=3). RGS2 protein (relative to β-
tubulin) at each time point was normalized to the corresponding 0 minute time point. The 
resultant half-life of tM33 RGS2 17.3 ± 4.3 minutes. The gray line represents full-length wild-
type RGS2 degradation in Figure 3.1. (B) Representative immunoblots of tM33 RGS2 after 
treatment with CHX or vehicle. The first panel represents tM33 RGS2 treated with CHX and 
the second panel represents the analogous β-tubulin treated with CHX. The lower two 
immunoblots represent tM33 RGS2 in cells treated with DMSO at 0.05% and cells treated with 
DMSO and probed for β-tubulin. 
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Figure 3.8. tM5 RGS2 Degradation. tM5 RGS2 was treated with CHX over 320 min. The 
figure represents the only instance out of 8 experiments in which tM5 RGS2 was detectable. 
Treatment with CHX further exacerbated the limited detection. Thus, the half-life for tM5 
RGS2 could not be determined.  
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approximately double the half-life of full-length RGS2, whereas tM33 RGS2 showed a half-
life comparable to full-length RGS2. The mechanism underlying these different half-lives 
remains unknown, but may reflect altered recognition by the ubiquitin-ligase enzymes which 
attach ubiquitin proteins for recognition by proteasomes. It might be advantageous to take a 
closer look at the amino acids near the N-terminus of each construct; it has been suggested that 
some specific amino acids are more likely to support degradation than others5–9. It should also 
be noted that tM16 RGS2 in some experiments increased in expression at the 5 and 10 min 
time points compared to the non-treated lysates. Cellular stress is known to increase RGS2 
mRNA and protein expression10. However, this only seemed to occur in the tM16 RGS2 
construct. tM33 RGS2 had a half-life comparable to that of full-length wild-type RGS2 
suggesting that there is not a need for this initiation variant to be upregulated. 
3.2 DEGRADATION PATHWAY FOLLOWED BY RGS2 
Due to the altered half-lives associated with RGS2 mutations and initiation variants, we were 
particularly interested in determining how RGS2 is degraded. The most common intracellular 
protein degradation pathway is the ubiquitin-proteasome pathway, where ubiquitin is added to 
a protein that is then recognized by the proteasome and ultimately degraded. This is a rapid, 
common process, and by inhibiting the pathway, we can determine if levels of RGS2 are 
changed via this route. 
3.2.1 INHIBITION OF PROTEASOMAL DEGRADATION ALTERS CELLULAR LEVELS 
OF WILD-TYPE RGS2 AND THE MAJORITY OF RGS2 SNPS 
MG132 is a well-established peptide aldehyde that can inhibit many types of proteases11–13. 
Due to this property, MG132 is considered a proteasome inhibitor and has been used 
extensively to determine whether a particular protein is degraded via proteasomes11–14. If the 
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expression level of a protein increases upon MG132 treatment, it suggests that under normal 
conditions, the protein is degraded by the ubiquitin-proteasome pathway. Transfected HEK293 
cells were subjected to MG132 or DMSO (vehicle) treatment for 2 h, lysed, and 
immunoblotted. Full-length wild-type RGS2 as well as RGS2 M5V expression increased when 
cells were treated with MG132 (Figure 3.9). However, RGS2 G23D levels did not change upon 
MG132 treatment (Figure 3.9). This result was unexpected as we hypothesized that each RGS2 
construct would increase expression level in the presence of MG132. It is interesting to note 
that RGS2 G23D had a longer half-life than full length wild-type RGS2 (Figure 3.3). This 
could be attributed to RGS2 G23D being more stable intracellularly. It would thus appear not 
be degraded by the ubiquitin-proteasome pathway. Ultimately, our results demonstrate that 
full-length wild-type RGS2 levels increase in the presence of a proteasome inhibitor. This 
suggests that under basal conditions, RGS2 is rapidly degraded by proteasomes.  
Analogous experiments were performed with RGS2 R14I and RGS K18N. Transfected 
HEK293 cells were subject to MG132 or DMSO treatment. Full-length wild-type RGS2 was 
again significantly increased when treated with MG132. RGS2 R14I and RGS2 K18N were 
also increased with MG132 treatment (Figure 3.10). RGS2 R14I and RGS2 K18N were found 
to have half-lives respectively shorter than and comparable to full-length wild-type RGS2, and 
taken together the data suggest that these RGS2 SNPs could also be degraded via the ubiquitin-
proteasomal pathway. These results suggest that under basal conditions, RGS2 is rapidly 
degraded via proteasomes and inhibiting these proteasomes significantly increases intracellular 
levels of RGS2.  
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Figure 3.9. RGS2 expression in the absence or presence of MG132. (A) Effect of 2 h, 20 μM 
MG132 (proteasome inhibitor) treatment and single point mutations on cellular levels of 
FLAG-tagged RGS2 constructs, normalized to β tubulin (n=4). Group data are presented as 
means ± SEM. Data were compared by two-way analysis of variance (ANOVA) and were 
further evaluated by Bonferroni post-test. Observed levels of RGS2 WT and RGS2 M5V 
**p<0.01 and ***p<0.001, respectively. (B) Representative immunoblot of mutant RGS2 
constructs in the absence and presence of MG132 
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Figure 3.10. RGS2 expression in the absence or presence of MG132. (A) Effect of 2 h, 20 μM 
MG132 (proteasome inhibitor) treatment and single point mutations on cellular levels of 
FLAG-tagged RGS2 constructs, normalized to β tubulin (n=5). Group data are presented as 
means ± SEM. Data were compared by two-way analysis of variance (ANOVA) and were 
further evaluated by Bonferroni post-test.  Observed levels of RGS2 WT, RGS2 R14I, RGS2 
K18N ***p<0.001, and *p<0.05. (B) Representative immunoblot of mutant RGS2 constructs 
in the absence and presence of MG132 
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3.2.2 INIHIBITION OF PROTEASOMAL DEGRADATION INCREASES CELLULAR 
LEVELS OF ALL RGS2 INITIATION VARIANTS  
Similar to our experiments on the mutant forms of RGS2, we examined whether the different 
initiation site variants had altered expression levels in the presence of MG132. A pseudo-
Kozak sequence was placed before each methionine to ensure that the methionine of interest 
was initiating translation. Independent of which initiation variant was produced, the relative 
levels of protein increased with MG132 treatment (Figure 3.11). This result is consistent with 
the half-life experiments, where tM16 RGS2 had a much longer half-life than the other 
constructs (Figure 3.6). 
  
3.3 INOSITOL-PHOSPHATE TURNOVER 
Further studies were carried out to determine whether the altered half-lives of RGS2 mutations 
and initiation variants might correspond to any effect on the ability of RGS2 to attenuate Gαq/11 
signaling. Wild-type RGS2 has been reported to attenuate Gαq/11 signaling15. It is possible that 
RGS2 mutations or initiation variants may differ from the full-length wild type protein in their 
abilities to attenuate Gαq/11 signaling, however relatively few alternate forms of RGS2 have 
been tested. 
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Figure 3.11. RGS2 expression in the absence or presence of MG132. (A) Effect of 2 h, 20 μM 
MG132 treatment on full-length RGS2 and truncations prior to each initiator methionine 
residue on the cellular levels of FLAG-tagged RGS2 constructs, normalized to β tubulin (n=5). 
Group data are presented as means ± SEM. Data were compared by two-way analysis of 
variance (ANOVA) and were further evaluated by Bonferroni post-test. Observed levels of full 
length wild-type RGS2, and variants with a pseudo-Kozak sequence prior to M5, M16 and 
M33 all increased in the presence of MG132, ***p<0.001, **p<0.01, and *p<0.05. (B) 
Representative immunoblot of full-length wild-type RGS2 expression and truncation mutants 
in the absence and presence of MG132.  
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3.3.1 RGS2 SNPS AFFECT Gαq/11 SIGNAL ATTENUATION 
IP3 is generated by the activation of phospholipase Cβ by Gαq/11. However, it is a challenge to 
measure IP3 levels due to its rapid turnover
16. Fortunately, IP3 is broken down into inositol-
phosphates which are stable in the presence of lithium and can be measured using a well-
established technique16,17. Inhibitory effects of RGS proteins on Gαq/11-PLC-β signaling are 
manifested as decreases in GPCR agonist potency and/or maximal effect. HEK293 cells 
transiently transfected with plasmid encoding the 5-HT2AR were loaded with myo-[
3H]-
inositol overnight and then stimulated with increasing concentrations of 5-HT. Full-length 
wild-type RGS2 (EC50 = 0.28 ± 0.18 μM) as well as RGS2 M5V (EC50 = 0.084 ± 0.032 μM) 
and RGS2 G23D (EC50 = 0.75 ± 0.68 μM) each yielded a rightward shift in the 5-HT dose-
response curve compared to the 5-HT2AR (EC50 = 0.066 ± 0.036 μM) by itself (Figure 3.12). 
Though RGS2 M5V yielded a rightward shift, it is much smaller than the effect of full-length 
wild-type RGS2 suggesting that this construct has decreased stability. The greater rightward 
shift of RGS2 G23D suggests that this construct has an increased ability to attenuate 5-HT2AR 
compared to full-length wild-type RGS2, consistent with its slower degradation. The reduced 
Emax observed in cells transfected with RGS2 G23D, along with the increased EC50, imply 
decreased receptor reserve with RGS2 G23D present. Ultimately, our results show that 1) 
RGS2 has the ability to attenuate the Gαq/11 coupled 5-HT2AR alone and 2) mutations within 
the N-terminus of RGS2 affect the degree to which it can attenuate Gαq/11 signaling.  
An analogous set of experiments was performed using two other RGS2 mutants, RGS2 R14I 
and RGS2 K18N. Both RGS2 R14I (EC50 = 0.28 ± 0.15 μM) and RGS2 K18N (EC50 = 0.50 ± 
0.23 μM) yielded a rightward shift in the dose-response curve compared to 5-HT2AR alone 
(EC50 = 0.065 ± 0.025 μM) (Figure 3.13). This suggests that both of these RGS2 constructs  
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Figure 3.12. Stimulation of phospholipase Cβ activity by 5-HT2AR signaling. Dose response 
curve for 5-HT mediated IP formation in response to treatment with increasing concentrations 
of 5-HT for 30 minutes in HEK293 cells transfected with a total of 2 μg of plasmid DNA 
expressing 5-HT2AR, plus either an RGS2 construct, or pcDNA3.1 as a transfection control. 
The data shown are the means ± S.E.M. of three independent experiments. For each 
experiment, during the fitting procedure the lower asymptote was constrained to be equal for 
all four data sets. The resultant fitted parameters were then averaged for each of the four 
experimental conditions and used to generate the lines shown. The EC50 for 5-HT2AR-mediated 
IP formation in the absence of transfected RGS2 was found to be 0.066 ± 0.036 μM, whereas 
the corresponding values with full-length wild-type RGS2, RGS2 M5V, and RGS2 G23D were 
found to be 0.28 ± 0.18 μM, 0.084 ± 0.032 μM, and 0.75 ± 0.68 μM, respectively. EC50 values 
were compared by one-way analysis of variance (ANOVA) and were further evaluated by 
Bonferroni post-test. Observed EC50 values for 5HT2AR + FL-RGS2 and 5HT2AR + RGS2 
G23D compared to 5HT2AR + pcDNA3.1 increased, p<0.01 and p<0.001, respectively. 
5HT2AR + RGS2 M5V did not significantly change (p>0.05).  
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Figure 3.13. Stimulation of phospholipase Cβ activity by 5-HT2AR signaling. Dose response 
curve for 5-HT mediated IP formation in response to treatment with increasing concentrations 
of 5-HT for 30 minutes in HEK293 cells transfected with a total of 2 μg of plasmid DNA 
expressing 5-HT2AR, plus either an RGS2 construct, or pcDNA3.1 as a transfection control. 
The data shown are the means ± S.E.M. of three independent experiments. For each 
experimental, during the fitting procedure the lower asymptote was constrained to be equal for 
all four data sets. The resultant fitted parameters were then averaged for each of the four 
experimental conditions and used to generate the lines shown. The EC50 for 5-HT2AR-mediated 
IP formation in the absence of transfected RGS2 was found to be 0.065 ± 0.25 μM, whereas 
the corresponding values with full-length wild-type RGS2, RGS2 R14I and RGS2 K18N were 
found to be 0.55 ± 0.25 μM, 0.19 ± 0.15 μM and 0.50 ± 0.23 μM, respectively. EC50 values 
were compared by one-way analysis of variance (ANOVA) and were further evaluated by 
Bonferroni post-test. Observed EC50 values for 5HT2AR + FL-RGS2, 5HT2AR + RGS2 R14I, 
and 5HT2AR + RGS2 K18N compared to 5HT2AR + pcDNA3.1 increased, p<0.001, p<0.01, 
and p<0.001, respectively.  
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are able to attenuate Gαq/11 signaling but to different degrees. RGS2 K18N, which had a half-
life comparable to that of full-length wild-type RGS2, also had a similar log EC50 value to the 
wild-type construct (EC50 = 0.55 ± 0.25 μM). These results, along with the RGS2 M5V and 
RGS2 G23D experiments, suggest that the ability of RGS2 to attenuate Gαq/11 can depend on 
the half-life of the protein as the constructs with the longer half-lives (e.g., RGS2 G23D) tended 
to produce greater rightward shifts in the 5-HT dose-response curve. 
3.3.2 RGS2 INITIATION VARIANTS AFFECT Gαq/11 SIGNAL ATTENUATION 
Experiments analogous to those performed using the RGS2 mutations (Section 3.2.1) were also 
performed with the four RGS2 initiation variants. Regardless of which RGS2 construct was 
transfected with 5-HT2AR, there was a rightward shift in the EC50 (Figure 3.14), including the 
minimal shift with that tM5 RGS2 construct that had an immeasurably short half-life. The EC50 
values of 5-HT in cells transfected with the 5-HT2AR plus full-length RGS2, tM5 RGS2, tM16 
RGS2, and tM33 RGS2 were found to be 0.27 ± 0.17 μM, 0.11 ± 0.04 μM, 0.67 ± 0.60 μM, 
and 0.46 ± 0.30μM respectively, compared to 0.072 ± 0.035 μM for 5-HT2AR alone. The 
rightward shifts in these dose-response curves suggest that independent of which initiation site 
is used, RGS2 has the ability to attenuate Gαq/11 coupled receptor signaling, but to varying 
extents. The degree to which RGS2 attenuates receptor signaling is roughly proportional to the 
half-life of a given initiation variant, as shown in Section 3.1.2. For example, tM5 RGS2 had 
an immeasurably short half-life (<5 min) and was the least able to attenuate inositol-phosphate 
formation, whereas tM16 RGS2 had the longest half-life (34.5 min) and also had the greatest 
ability to attenuate inositol phosphate formation and even lowered the Emax.  
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Figure 3.14. Stimulation of phospholipase Cβ activity by 5-HT2AR signaling. Dose response 
curve for 5-HT mediated IP formation in response to treatment with increasing concentrations 
of 5-HT for 30 minutes in HEK293 cells transfected with a total of 2 μg of plasmid DNA 
expressing 5-HT2AR, plus either an RGS2 construct, or pcDNA3.1 as a transfection control. 
The data shown are the means ± S.E.M. of three independent experiments. For each 
experimental, during the fitting procedure the lower asymptote was constrained to be equal for 
all four data sets. The resultant fitted parameters were then averaged for each of the four 
experimental conditions and used to generate the lines shown. The EC50 for 5-HT2AR-mediated 
IP formation in the absence of transfected RGS2 was found to be0.072 ± 0.035 μM, whereas 
the corresponding values with full-length RGS2, tM5 RGS2, tM16 RGS2, and tM33 RGS2 
0.27 ± 0.17 μM, 0.11 ± 0.04 μM, 0.67 ± 0.60 μM, 0.46 ± 0.30 μM respectively. EC50 values 
were compared by one-way analysis of variance (ANOVA) and were further evaluated by 
Bonferroni post-test. Observed EC50 values for 5HT2AR + FL-RGS2, 5HT2AR + tM16 RGS2, 
and 5HT2AR + tM33 RGS2 compared to 5HT2AR + pcDNA3.1 increased, p<0.01, p<0.001, 
and p<0.01, respectively. 5HT2AR + tM5 RGS2 did not significantly change (p>0.05). 
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3.3.3 CORRELATION BETWEEN RGS2 AND Gαq/11 SIGNAL ATTENUATION 
We wanted to determine if there was a correlation between the half-life of RGS2 constructs 
and their abilities to attenuate Gαq/11 signaling. The average half-life and EC50 values from 
Sections 3.1 and 3.2, respectively, were graphed (Figure 3.15). tM5 RGS2 was arbitrarily 
given a half-life of 5 min due to our inability to consistently detect this construct via 
immunoblotting (Figure 3.8). There appears to be a correlation between the half-life and EC50 
in that as the half-life increases, so does the EC50. This suggests that when RGS2 is more stable 
in a cell, it also functions to attenuate signal to a greater degree. It should be noted that this is 
not a perfect correlation (r2 = 0.8004). The low r2 value could be due to inter-experimental 
variability and/or differences in translation efficiency between RGS2 variants. 
To summarize, our data reveal that small changes in the amino acid sequence of RGS2 can 
have substantive effects on its rate of degradation, and thus on its ability to regulate signaling. 
Simply mutating one amino acid in the N-terminal region of RGS2 can alter its half-life, which 
in turn can affect the ability of the protein to attenuate Gαq/11 signaling. For instance, RGS2 
M5V was shown to have a half-life shorter than full-length wild-type RGS2 (Figure 3.2) which 
may result in the decreased ability to attenuate Gαq/11 signaling (Figure 3.12). The opposite 
outcome was seen for the most stable variant tested, RGS2 G23D (Figure 3.3). Additionally, 
the majority of RGS2 construct’s intracellular levels increased with proteasomal inhibition 
suggesting, that under basal conditions, RGS2 is degraded via the ubiquitin proteasomal 
pathway (Figure3.9-Figure 3.11).  
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Figure 3.15. Correlation between half-life and EC50. Positive correlation between the average 
half-life of an RGS2 construct and the EC50 of 5-HT in cells expressing 5-HT2AR plus the given 
RGS2 variant. tM5 RGS2 was arbitrarily assigned a half-life of 5 min. Data shown are 
representative of the averages found in 3-5 independent experiments. Experiments were not 
done simultaneously.  
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4 DISCUSSION 
4.1  SUMMARY OF NOVEL FINDINGS AND CONCLUSIONS 
Although recent studies have indicated that RGS2 contains multiple initiation sites1 and can 
contain numerous SNPs2,3, it is unknown whether these different isoforms have any effect on 
RGS2 regulation. Our data suggest that even minor changes in the N-terminus of RGS2 can 
have a profound effect on RGS2 regulation. We show for the first time altered degradation 
rates between RGS2 initiation variants and also RGS2 mutations. Additionally, the altered 
half-lives appear to be causing differences in RGS2 mediated Gαq/11 signal attenuation. 
Furthermore, we present data suggesting that RGS2 is rapidly degraded via the ubiquitin-
proteasome pathway. The altered degradation rates may be due to how quickly each RGS2 
protein is recognized and degraded via the ubiquitin-proteasome pathway. Since RGS2 is a 
ubiquitously expressed protein and regulates the signaling of many GPCRs, it is most prudent 
to understand how any changes within the N-terminus of RGS2 could have significant effects 
on Gα signaling.  
Study A: To determine the stability of wild-type and mutant forms of RGS2. 
We demonstrated that the use of each initiator methionine residue alters the half-life of RGS2. 
Furthermore, mutations within the N-terminal region of RGS2 also have a strong impact on 
protein half-life. This becomes important when one considers the major biological function 
RGS2 has within a cell, which is to attenuate Gα signaling. We also presented evidence 
suggesting that under basal conditions, wild-type RGS2 is rapidly degraded via the ubiquitin-
proteasome pathway. This holds true regardless of which initiator methionine begins 
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translation. It also appears the mutant forms of RGS2 are degraded via the same pathway with 
exception to RGS2 G23D. It was interesting that the RGS2 mutant with the longest half-life, 
RGS2 G23D, was unaffected by MG132 treatment. MG132 is a nonspecific inhibitor of the 
ubiquitin-proteasome pathway meaning when the drug is present within a cell, the vast majority 
proteins that are degraded in such a fashion should increase in cellular abundance. Individuals 
carrying this point substitution have a phenotypic profile including borderline IQ, hirsutism, 
increased bone alkaline phosphatase and decreased platelet Gαs function; all phenotypes 
indicative of decreased Gαs signaling3. It has been shown that RGS2 G23D causes a 
preferential shift in translation to the two longest isoforms of RGS2 which contains a putative 
adenylyl cyclase binding domain3. Since RGS2 G23D levels were unaffected by proteasome 
inhibition and had an increased half-life relative to full-length wild-type RGS2 levels, it would 
be reasonable to assume these attributes of the point substitution are what is leading to such a 
robust phenotype. Gα signaling is undoubtedly an important signaling pathway and if an RGS2 
mutant attenuates the signal to a greater degree than what is expected, one would anticipate 
some sort of physiological complication.  
Study B: To determine the effects of wild-type and mutant forms of RGS2 on G protein-
mediated signaling 
We showed that an increase or decrease in the half-life of RGS2 compared to the full-length 
wild-type RGS2 was respectively proportional to an increase or decrease in Gαq/11 signal 
attenuation (Figure 3.15). Interestingly, RGS2 M5V and RGS2 G23D, which have been 
associated with physiological consequences, had a respective decrease or increase in the ability 
to attenuate Gαq/11-mediated signaling (Figure 3.12). Furthermore, RGS2 initiation variants 
had altered abilities to mitigate Gαq/11 signaling (Figure 3.14) proportional to the half-lives 
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determined in Study A. Therefore, individuals carrying a mutant form of RGS2 may experience 
phenotypes associated with Gα signaling, not because RGS2 is ineffective but because the 
altered half-life of RGS2 has caused a shift in the expected degree of Gα signaling. 
4.2 CONTRIBUTIONS OF RESEARCH TO CURRENT STATE OF KNOWLEDGE 
GPCRs are an integral part of signaling systems, allowing extracellular signals from a broad 
range of ligands to be turned into intracellular responses4. Excessive GPCR signaling can lead 
to many pathophysiological conditions including hypertension5, stress, anxiety, depression6, 
and many endocrine disorders7. It is therefore necessary to have well regulated mechanisms 
for GPCR deactivation. There are intrinsic mechanisms for GPCR deactivation8 but this 
process can be accelerated by GAPs such as RGS proteins, and indeed RGS proteins in many 
instances are necessary for normal signaling to take place9. There are many RGS proteins each 
with variable tissue distribution profiles, Gα protein specificity, and all must have mechanisms 
for regulation. For example, RGS4 and RGS5 have been extensively researched and they both 
have been identified as proteins that are rapidly degraded via the ubiquitin proteasome 
pathway10,11. We have shown that wild-type RGS2 is likely degraded in the same fashion, 
although its degradation is somewhat less rapid than occurs with RGS4 and RGS511. We have 
also shown that the N-terminus of RGS2 is important in determining how it is regulated. 
Previous research showed that truncation of the N-terminus of RGS2 results in loss of function, 
suggesting that the N-terminus may have a role in plasma membrane targeting12. We indicated 
that N-terminal modifications, whether due to the use of initiation variants or introducing 
mutations, can have severe effects on RGS2 regulation and therefore, G protein signal 
attenuation. The N-end rule is only interested in the first two amino acids yet we found 
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substitutions farther into the N-terminus had profound effects on degradation. This concept 
will be discussed in Section 4.3. 
Individuals carrying certain RGS2 SNPs show particular phenotypes2,3 but it remains unknown 
as to why these pathological consequences occur. RGS2 M5V has been tentatively associated 
with hypertension2 but the evidence is not yet compelling due in part to the low population 
frequency of the SNP. However, our data suggest that RGS2 M5V has a relatively short half-
life compared to the full-length wild-type RGS2 and also has a decreased ability to attenuate 
Gαq/11 signaling, which might be expected to result in increased Gαq/11 signaling. Excessive 
Gαq/11 signaling is a factor which can lead to hypertension and eventually cardiac 
hypertrophy13. Knowing this allows our data to strengthen the hypothesis that RGS2 M5V may 
be associated with hypertension. Interestingly, there is a genetic defect called 
Bartter’s/Gitelman’s syndrome where individuals have the classic characteristics of 
hypertension (activation of the renin-angiotensin-aldosterone system, increased angiotensin II 
and aldosterone, hypokalemia, and sodium depletion), yet are normo/hypotensive due in part 
to increased cellular RGS2 levels14. Individuals carrying the RGS2 G23D mutation have a 
phenotypic profile including borderline IQ, hirsutism, increased bone alkaline phosphatase, 
and decrease platelet Gαs function, all characteristics seen in patients with a Gαs hypofunction 
condition known as Albright hereditary osteodystrophy (AHO)3. The authors concluded that 
this mutant RGS2 protein has an increased inhibitory effect on cAMP production due to a 
preference of the ribosomal machinery for translation initiation sites 1 and 5, which contain a 
putative adenylyl cyclase binding domain at amino acids 9-113. Our data is consistent with the 
idea that RGS2 G23D will have an increased ability to inhibit Gα signaling but it may be more 
complex than the use of differential initiation sites. Based on the findings presented in this 
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thesis, we propose that RGS2 G23D has an increased half-life relative to the full-length wild-
type form of RGS2 which will present a greater chance of RGS2 binding and inhibiting Gα-
mediated signals; this phenomenon will only enhance the tendency towards decreased Gαs (and 
Gαq/11) signaling in individuals who harbour the RGS2 G23D point mutation. 
We also investigated two other RGS2 mutations with no known phenotypes, RGS2 R14I and 
RGS2 K18N (genecards.org). Our findings with these mutations reinforce our other findings 
which suggest that the half-life of an RGS2 protein is proportional to the ability to inactivate 
Gαq/11 signaling. RGS2 R14I had a relatively short half-life of ~6 minutes. It would be 
interesting to determine if individuals with this mutation present any phenotypes associated 
with excessive Gα signaling, such as hypertension. RGS2 K18N on the other hand has a half-
life comparable to full-length wild-type RGS2 and the only research done on this SNP shows 
it is not associated with hypertension15. This would seem reasonable as this mutation has a 
nearly identical ability to attenuate Gαq/11 signaling as full-length wild-type RGS2. Overall, 
our data shows how important the N-terminus is within RGS2 and any manipulation in the 
amino acid sequence can affect how RGS2 is regulated and how it functions.  
4.3 RGS2 IS DEGRADED VIA THE UBIQUITIN-PROTEASOME PATHWAY 
Previous research has suggested that like RGS4 and RGS5, RGS2 may be degraded via the 
ubiquitin-proteasome pathway10,16. Our results propose that this hypothesis is correct at least 
for most variants of RGS2. Figure 1.5 shows the classical N-end rule pathway, where the amino 
acid next to the initiator methionine is imperative in predicting if, and how rapidly, the protein 
is ubiquitinated and degraded. It is unknown at what rate each process happens, for example, 
whether deamidation by NTAN NtN-amidase is quicker than NTAQ NtQ-amidase, or vice 
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versa. The overall process of degradation is likely due to the entire protein structure, but our 
results propose modifications to the classical pathway. Full-length wild-type RGS2 has a 
glutamine (Q) at amino acid position 2. Glutamine, according to the current formulation of the 
N-end rule pathway, is a tertiary destabilizing residue which must undergo deamidation to 
glutamic acid (E), arginylation to add a destabilizing arginine, and then recognition by N-
recognins (E3’s) and eventually degradation. Our results, as well as previous results17, show 
full-length wild-type RGS2 to have a half-life of approximately 17.5 minutes. On the other 
hand, we found tM16 RGS2 to have a half-life of approximately 34.5 minutes, yet it contains 
a secondary destabilizing residue (aspartic acid, D) at amino acid position 2. Considering tM16 
RGS2 has one less step than full-length wild-type RGS2 in the degradation pathway, it is 
realistic to assume that this form of RGS2 would be degraded more rapidly. To complicate 
things further, tM5 RGS2, which had an immeasurably short half-life in our hands (<5 min), 
and tM33 RGS2, which had a comparable half-life to the full-length RGS2 (17.3 min), both 
have primary destabilizing residues at amino acid position 2, phenylalanine (F) and lysine (K), 
respectively, yet different half-lives. This could indicate that there is a difference between Type 
1 and Type 2 primary destabilizing residues of the N-end rule pathway. However, it is evident 
that the number of steps in the degradation pathway need not be proportional to the degradation 
rate.  
Another potential contributor to the altered half-lives are the amino acid sequences further 
downstream of the initiator methionine. The N-end rule emphasizes the role of the second 
amino acid, however, the RGS2 G23D mutation has a substantial effect on the protein’s half-
life and moreover cellular levels are not affected by MG132 treatment, implying a lack of 
proteasomal degradation. Therefore, it is reasonable to assume that amino acids further 
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downstream of the initiation site can strongly influence proteasomal degradation. It is 
interesting to note that the full-length wild-type RGS2 and tM5 RGS2 only have a four amino 
acid difference yet such a large variability in half-lives. This could be in consequence of tM5 
RGS2 having two primary destabilizing residues in a row (phenylalanine and leucine) whereas 
full-length RGS2 only has a tertiary destabilizing residue (glutamine) followed by a residue 
not associated with the N-end rule (serine), otherwise referred to as a stabilizing residue. 
Ultimately, our results indicate that the N-end rule is not a perfectly formulated pathway and 
even minor changes in the N-terminus of a protein can affect how rapidly it is degraded.  
4.4 RGS2 MUTATIONS AS TARGETED GENE THERAPY 
A common problem with hypertension and hypertrophic hearts, at least in animal models, is 
the expression and function of RGS2 is markedly decreased, which is accompanied with 
exacerbated Gαq/11 signaling18. Previous research has shown RGS2 as an intrinsic suppressor 
of hypertension and cardiac hypertrophy18,19. Therefore, if the expression of RGS2 could be 
restored or if the GAP activity of RGS2 were to be increased, this could represent a promising 
direction in treating particular cardiovascular diseases such as hypertension18. An interesting 
new area of drug treatment is personalized medicine or gene therapy. Gene therapy is the 
therapeutic delivery of nucleic acid polymers via vectors into a patient’s cells to treat disease 
by interfering with protein expression or possibly altering genetic mutations20. There is a lot 
of controversy and there are many unknowns about using gene therapy as a treatment for 
diseases, most notably cancer20. However, if gene therapy can alter genetic mutations, it would 
not be a stretch to assume we could alter wild-type genes to mutant forms. For instance, since 
RGS2 is markedly decreased in hypertensive patients, introducing the RGS2 G23D mutant into 
the cardiovascular system of a patient might allow for a functional form of RGS2 to be 
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produced while also attenuating Gαq/11 to a greater degree than wild-type RGS2. Alternatively, 
phenotypes associated with low Gα protein activity, such as platelet Gαs hypofunction3 or 
enhanced accumulation of glycogen and heat resistance21, may benefit from introducing the 
RGS2 M5V mutation into the genome as opposed to the wild-type form. Undoubtedly, these 
are hypothetical treatment options. Nevertheless, altering a protein may limit adverse effects 
of commonly prescribed medications like angiotensin II receptor antagonists, as you are simply 
varying the amount of Gα signaling instead of completely impeding the action of a receptor. If 
these hypotheses are to be tested, the molecular mechanisms regulating RGS2 must first be 
uncovered. Our results provide evidence that RGS2 mutations can modify that rate of Gα 
signaling, hence it is important to know how a mutation effects the action of a protein before 
attempting to target it for therapeutic means.  
4.5 RGS2 INITIATION VARIANTS  
ATF4 is an example of a gene with multiple initiation sites, however, these initiator 
methionines are important for the action of the protein. Under basal, non-stressed conditions, 
two upstream open reading frames are translated which results in the exclusion of functional 
ATF4 due to an out of frame shift22. However, under stressful conditions (where initiation is 
delayed), the ribosome bypasses the upstream open reading frames and initiates translation at 
the ATF4 open reading frame. Therefore, ATF4 is increased in response to stress and can 
proceed to act as a transcription factor and attempt to mitigate the stressful event on the cell22. 
In contrast to ATF4, RGS2 has four initiator methionines1 yet there is little or no understanding 
of why these alternative initiation variants, which appear to be conserved among multiple 
species, would need to exist. RGS2 does contain multiple domains including a GAP domain 
and a plasma membrane association domain1, however both are downstream of each initiator 
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methionine suggesting all the RGS2 variants encompass both domains. It has been suggested 
that RGS2 has an adenylyl cyclase inhibitory domain between residues 9-111,3. It has also been 
proposed that upon Gαs-coupled receptor activation, the longest isoform of RGS2 is 
preferentially translated in order produce an RGS2 isoform with the adenylyl cyclase inhibitory 
domain1. The concern with this hypothesis is it remains controversial if RGS2 in fact binds 
adenylyl cyclase, Gαs, or both, during its inhibitory effect on this signaling pathway. Previous 
research shows that RGS2 protein can be immunoprecipitated with purified or cellular Gαs23,24. 
If RGS2 is able to impede Gαs signaling without binding to adenylyl cyclase, in other words, 
with the remaining residues downstream of methionine 33, the adenylyl cyclase inhibitory 
domain would appear to be a redundant mechanism. Another hypothesis for the four initiator 
methionines is that certain isoforms may be produced in times of stress. For instance, RGS2 is 
known to be able to arrest de novo protein synthesis during times of cellular stress25. As with 
other proteins that play a role in the stress response, downstream open reading frames of RGS2 
(i.e., tM16 RGS2 and tM33 RGS2) may be more likely to be utilized by the ribosomal 
machinery during cellular stress. In the case of tM16 RGS2, this would result in a protein with 
a longer half-life. Again, this is simply a hypothesis and there still remains no convincing 
evidence for the need of the four initiator methionines.  
Our results are consistent with the finding of another group, wherein under basal conditions, 
tM16 RGS2 was determined to be the most highly expressed initiation variant in cells 
transfected with the full RGS2 mRNA sequence (i.e., lacking any Kozak sequence)1. However 
in that study, RGS2 degradation was not considered and the present results suggest that slower 
degradation of tM16 RGS2 could also have contributed to its greater abundance. We 
hypothesize that this may be due to energy conservation. Simply by looking at the half-lives 
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of the RGS2 initiation variants we can see that RGS2 is a rapidly turned over protein. When 
there is limited GPCR activation, there is minimal need for RGS proteins. Therefore, it would 
be energy efficient for the cell to produce a shorter isoform of RGS2 and an isoform that was 
more stable. tM16 RGS2 maintains the ability to traffic RGS2 to the plasma membrane upon 
receptor stimulation1 and is still able to attenuate Gαq/11 signaling. The flaw with this 
hypothesis is tM33 RGS2 also maintains the ability to traffic RGS2 to the plasma membrane1 
and can attenuate Gαq/11 signaling, but does not have as long of a half-life as tM16 RGS2. 
There may be a domain between M16 and M33 that remains critical to RGS2 that causes a 
preference of tM16 to be translated. Obviously, these concepts have not been tested and we 
cannot say for sure why tM16 RGS2 is preferentially translated as opposed to other RGS2 
initiation variants. 
4.6 FUTURE DIRECTIONS  
Our research has revealed that variations in the N-terminus of RGS2 can affect both the 
stability of the protein and its inhibitory activity. Nonetheless, there remain mechanisms that 
need to be elucidated about RGS2 regulation and the activity of naturally occurring RGS2 
variants. RGS2 is known to attenuate Gαs signaling24 however, our research only focused on 
Gαq/11-mediated signaling. Therefore, it would be prudent to perform cAMP experiments that 
will help determine the ability of RGS2 isoforms to inhibit Gαs signaling. Such experiments 
will help clarify multiple mechanisms including if the degradation rate of an RGS2 protein is 
proportional to the ability to attenuate Gαs signaling, and in the process would also likely 
determine if the putative adenylyl cyclase binding domain is actually necessary for this 
inhibitory function. There is some evidence supporting the presence of an adenylyl cyclase 
binding domain between residues 9-11 of RGS2. Thus, if tM16 RGS2 and tM33 RGS2 are 
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unable to reduce Gαs signaling, this would suggest the domain is essential. However, if both 
shorter isoforms of RGS2 are able to attenuate Gαs signaling, there are several possible 
explanations. First, an additional adenylyl cyclase binding domain may exist downstream of 
methionine 33. Second, RGS2 is able to bind to and inhibit both adenylyl cyclase and Gαs24. 
Third, the RGS domain of RGS2 can bind and inhibit both Gαq/11 and Gαs. All these hypotheses 
are testable to determine which, if any, are correct. These experiments may also help strengthen 
the claim that the G23D mutation in RGS2 causes a relative preference for the use of the 
translation initiation sites at positions 1 and 5 compared to the wild-type sequence3. This would 
only become important if it was determined that the putative adenylyl cyclase binding domain 
of RGS2 does exist. 
Further knowledge on the translational mechanisms of RGS2 could also be obtained in order 
to determine if one isoform of RGS2, i.e., tM16 RGS2, is translated preferentially over another 
isoform, i.e., tM5 RGS2, or if the difference we see if simply due to different rates of 
degradation. If a particular isoform of RGS2 is upregulated during times of stress, a simple 
experiment would be to stress cells known to contain wild-type RGS2, perform an immunoblot 
and compare stressed RGS2 initiation variants to a non-stressed control group. Since RGS2 is 
upregulated during times of stress25, total RGS2 should increase. However, if a particular 
isoform increases relatively to total RGS2, it can be assumed that this initiation variant is 
preferentially translated times of stress. Ideally, these experiments would be executed using 
primary cells in order to determine if this translational effect happens in vivo.  
Finally, to strengthen the argument that RGS2 is rapidly degraded via the ubiquitin proteasome 
pathway, two sets of experiments must be performed. First, RGS2-ubiquitin 
immunoprecipitation experiments should be done to ensure RGS2 is being ubiquitinated. 
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Previous research shows wild-type RGS2 to be ubiquitinated26 but this experiment needs to be 
repeated for the other RGS2 variants. Second, cells transfected with RGS2 constructs should 
be treated with other inhibitors of both the ubiquitin-proteasome pathway and the lysosomal 
pathway. This should confirm that RGS2 is degraded via the ubiquitin-proteasome pathway 
and may help determine how RGS2 G23D is degraded. If RGS2 G23D cellular levels increase 
in the presence of a lysosomal inhibitor, it would suggest that certain RGS2 mutations may be 
regulated differently than wild-type RGS2. 
4.7 CONCLUSION 
Our results provide evidence for the importance of the N-terminus of RGS2 in regards to both 
stability and activity of the protein. Any variation within the N-terminus can affect how rapidly 
RGS2 is degraded and the ability of the protein to attenuate Gα protein signaling. RGS2 is an 
extremely important protein and varying its ability to function can lead to pathophysiological 
consequences, as indicated by the RGS2 G23D mutation3. Therefore, we have shown that 
naturally occurring N-terminal variants of RGS2 affect stability and activity in vitro. 
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1 APPENDICES 
5.1 RGS2-LUCIFERASE PROTEIN DEGRADATION 
Originally, we wanted to take advantage of RGS2-luciferase fusion constructs to measure 
RGS2 stability and variability translation. The C-terminus of RGS2 constructs were fused with 
a renilla luciferase protein which, in theory, would emit light when RGS2 was synthesized. 
Thus, an increase in luminescence would be indicative of higher RGS2 levels. Unfortunately, 
luciferase has multiple initiator methionine residues which were preferentially chosen to 
initiate synthesis when mutations were introduced into the RGS2 protein. As seen in Figure 
5.1, the majority luminescence we were detecting was simply luciferase itself, not fused with 
RGS2.  
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Figure 5.1. RGS2-luciferase fusion proteins. RGS2-luciferase fusion constructs were 
immunoblotted with anti-renilla luciferase. 50 kDa correlates to RGS2 and luciferase fusion 
and 36 kDa correlates to luciferase alone. Constructs include: Rluc = empty renilla luciferase 
control plasmid; WT = full-length wild-type RGS2; M1 = methionine 5, 16, and 33 were 
mutated to alanine; M5 = methionine 1, 16, and 33 were mutated to alanine; M16 = methionine 
1, 5, and 33 were mutated to alanine; M33 = methionine 1, 5, and 16 were mutated to alanine; 
1STOP = a stop codon was introduced between methionine 1 and 5 of RGS2; M5L = 
methionine 5 was mutated to leucine; M5V = methionine 5 was mutated to valine; pkM1 = 
pseudo-Kozak sequence was introduced downstream of methionine 1; pkM5 = pseudo-Kozak 
sequence was introduced downstream of methionine 5; pkM16 = pseudo-Kozak sequence was 
introduced downstream of methionine 16; pkM33 = pseudo-Kozak sequence was introduced 
downstream of methionine 33. Renilla luciferase protein = 36 kDa whereas RGS2-luciferase 
fusion protein = 50 kDa. 
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